Review

Interactions between Autophagy and Bacterial Toxins: Targets for Therapy?

Jacques Mathieu 1,2

1 Department of Microbiology, Institut de Recherche Biomédicale des Armées (IRBA), BP 73, Bretigny-sur-orge cedex F-91223, France; E-Mail: jacques.mathieu@irba.fr or jacques.mathieu@pasteur.fr; Tel.: +33-660-234-814
2 Laboratoire Pathogénie des Toxi-infections Bactériennes, Institut Pasteur, 28 rue du Docteur Roux, Paris cedex 15 F-75725, France

Academic Editor: Holger Barth

Received: 1 April 2015 / Accepted: 28 July 2015 / Published: 4 August 2015

Abstract: Autophagy is a physiological process involved in defense mechanisms for clearing intracellular bacteria. The autophagic pathway is finely regulated and bacterial toxins interact with this process in a complex manner. Bacterial toxins also interact significantly with many biochemical processes. Evaluations of the effects of bacterial toxins, such as endotoxins, pore-forming toxins and adenylate cyclases, on autophagy could support the development of new strategies for countering bacterial pathogenicity. Treatment strategies could focus on drugs that enhance autophagic processes to improve the clearance of intracellular bacteria. However, further in vivo studies are required to decipher the upregulation of autophagy and potential side effects limiting such approaches. The capacity of autophagy activation strategies to improve the outcome of antibiotic treatment should be investigated in the future.

Keywords: bacterial toxins; autophagy; cyclic AMP; therapeutic targets

1. Introduction

Autophagy is a physiological process involved in regulating the overlapping or closely intertwined homeostasis, immunity and stress/survival responses (Figure 1). It also plays a major role in a broad range of human diseases, including cancer and neurodegenerative diseases [1,2].
Figure 1. A schematic diagram, taken from [1], depicting the key roles of autophagy in cellular processes, such as homeostasis, responses to stress, the survival pathway, and immunity to bacterial pathogens. Reproduced from [1]. Copyright 2015, Elsevier.

Autophagy is a tightly regulated process [3–6]. It is involved in the survival of cells subjected to different stress conditions, such as starvation. If autophagy levels are excessively high, the cell may undergo autophagic cell death, also known as type II programmed cell death (PCD), a process different from apoptosis (type I PCD) and necrosis [7–10].

Autophagy consists of several different pathways: microautophagy, chaperone-mediated autophagy, lipophagy, macroautophagy and xenophagy. Microautophagy involves the direct uptake of cytosol, inclusions (e.g., glycogen) and organelles (e.g., ribosomes, peroxisomes) into the lysosome/vacuole by the protrusion, invagination or septation of the sequestering organelle membrane [11–13]. Mitophagy is a selective degradation of mitochondria mediated by micro- or macroautophagic processes [14]. Chaperone-mediated autophagy (CMA) is an autophagic process in mammalian cells by which proteins containing a particular pentapeptide motif related to KFERQ are transported across the lysosomal membrane and degraded [15–17]. The translocation process requires the action of integral lysosome-associated membrane protein type 2 (LAMP-2A) and the 73 kD cytosolic and lysosomal luminal cognate heat shock proteins (hsc73) [18,19]. Lipophagy is a selective degradation of lipid droplets by lysosomes, contributing to lipolysis (breakdown of triglycerides into free fatty acids). In mammals, this selective degradation has been found to occur via macroautophagy (macrolipophagy) [20].

Macroautophagy is an autophagic process involving the formation of an autophagosome, a double- or multiple-membrane cytosolic vesicle of non-lysosomal/vacuolar origin [13]. Xenophagy is a cell-autonomous innate immunity defense mechanisms in which cells eliminate intracellular pathogens by capturing them in autophagosomes for subsequent killing [21]. In higher eukaryotes, the lysosome is a degradative organelle that compartmentalizes a range of hydrolytic enzymes and maintains a very low pH [13].
The elimination of intracellular pathogens by autophagy in mammalian cells (xenophagy) results not only in the degradation of invading bacteria, viruses, fungi and parasites, but also in the release of metabolites used by the pathogen during infection, thereby promoting cell survival. As recently reported by Devenish and Lai [22], the induction of autophagy results in the clearance of some bacterial pathogens, whereas other bacteria can manipulate autophagy for their own benefit and appear to replicate effectively within autophagosome-like vesicles.

Three different autophagic processes can be distinguished in relation to bacterial infections of mammalian cells: macroautophagy (xenophagy) [23], non-canonical autophagy [24] and microtubule-associated protein 1 light chain (LC3)-associated phagocytosis (LAP) [25]. These processes will be described in detail below.

Numerous bacterial pathogens interfere with the autophagy process, naturally involving defenses against intracellular bacteria. However, it has recently been shown that autophagy may play different roles after bacterial infection [26]: bacterial clearance, the coordination of cell-autonomous signaling, and in some cases, the promotion of bacterial replication.

The ability to survive within cells is crucial for several pathogenic bacteria. Following the invasion of their eukaryotic target cells, these bacteria are internalized within a membrane-bound vacuole that becomes more acidic as it develops into a mature degradative phagolysosome [27]. Some pathogens survive in this niche by either preventing vacuole-lysosome fusion or by modifying the environment within the phagolysosome. Certain bacteria have evolved means of escaping from the vacuole and continuing their life cycle within the cytosol [28–30]. Only a small number of bacteria are adapted for growth within the cytosol (reviewed in [31]).

Intracellular bacterial pathogens produce many virulence factors and toxins able to interfere with autophagy. These bacterial products include lipopolysaccharides (LPS), membrane-spanning secretion apparatuses such as those of Salmonella serovar Typhimurium and Mycobacterium tuberculosis, pore-forming toxins, such as those of Streptococcus pyogenes and Listeria monocytogenes, and bacterial adenylate cyclases. LPS is one of the most immunostimulatory components of the outer membrane of Gram-negative bacteria [32,33], capable of interfering with the autophagy machinery [34,35].

Many pathogenic bacteria produce pore-forming toxins (PFT), which are important virulence factors. These toxins are secreted as soluble monomers by the bacterium. They bind to a membrane receptor and multimerize, generating an amphipathic structure that serves as a pore. The cholesterol-dependent cytolsins, which use cholesterol as receptors [36], form a large family of pore-forming toxins produced by numerous bacteria, including Bacillus, Staphylococcus, Clostridium, Streptococcus, and Listeria. More than 600 putative bacterial adenylate cyclases have been identified [37], and cAMP seems to play a critical role in the autophagy pathway, as highlighted in a recent review [1].

This review focuses on two key questions: (1) Are the different interactions between autophagy and bacterial toxins involved in bacterial pathogenicity? (2) What therapeutic potential do molecules targeting the autophagy machinery have in cases of bacterial intoxication?

A brief overview of the mechanisms involved in autophagic pathways is required, to clarify the potential interactions between bacterial toxins and autophagy. However, we do not provide an exhaustive description of these mechanisms here, as autophagic pathways are complex and not all the detail is necessary to understand possible interactions. Many molecular agents are involved and the number of publications in this field is growing.
2. Overview of Autophagy Mechanisms

Autophagy is a physiological process in which cytoplasmic components, including organelles and intracellular microbes, are engulfed by single- or double-membrane vesicles and targeted for destruction by fusion with a lysosome (review in [1,38]). Autophagy adjusts cellular biomass and function in response to diverse stimuli, including infection [39]. It plays specific roles in shaping immune system development, fueling host innate and adaptive immune responses, and directly controlling intracellular microbes through cell-autonomous innate defense. As an evolutionary counterpoint, intracellular pathogens have evolved to block autophagic microbicidal defense and to subvert host autophagic responses for their own survival or growth. The ability of eukaryotic pathogens to deploy their own autophagic machinery may also contribute to microbial pathogenesis. Thus, a complex interplay between autophagy and microbial adaptations to autophagy governs the net outcome of host-microbe encounters.

Pathogen engulfment is initiated by the formation of a phagophore or isolation membrane that engulfs the cytoplasmic components to form a sealed double-membrane structure called an autophagosome. This structure fuses with endosomes or multivesicular bodies to form the amphisome, which then fuses with the lysosome to generate the autolysosome, in which sequestered material is degraded by the lysosomal proteases. Certain microbes make use of lipid raft components to enter the host cell and trigger autophagy [40]. Over 30 components of the molecular machinery involved in autophagy have been identified [3], including a large number described as autophagy-related proteins (Atgs) [41]. The mammalian ortholog of the yeast Atg8 protein, microtubule-associated protein 1 light chain 3 (LC3), is an important element of this machinery and a key marker of autophagosomal compartments [42]. The LC3 family includes LC3A, LC3B and LC3C. These proteins are involved in the biogenesis of autophagosomes, and in cargo recruitment [43]. Vertebrate LC3 is regulated by phosphorylation of the \( N \)-terminal helical region by protein kinase A [44]. After translation, LC3 is proteolytically processed by Atg4, which cleaves a \( C \)-terminal glycine to generate the LC3-I form. Subsequently, when autophagy is activated, LC3-I binds covalently to the lipid phosphatidylethanolamine to generate the membrane-bound LC3-II form [42]. This processing is accomplished by a ubiquitin-like conjugation system consisting of Atg7 and Atg3 (E1-like and E2-like enzymes, respectively) and the Atg5-Atg12-Atg16L1 complex (E3-like enzyme) [45].

Three different autophagy processes are triggered by bacterial infections of mammalian cells. The first of these processes is macroautophagy (xenophagy), which involves the recognition of intracellular bacteria and their sequestration in double-membrane vesicles called autophagosomes. The cellular machinery responsible for autophagosome production has recently been comprehensively reviewed [23]. LC3 is a key component and signature marker of the autophagosomal membrane. This protein must be conjugated to phosphatidylethanolamine for incorporation into the isolation membrane. During isolation membrane expansion, the cargo (bacteria in this context) is sequestered and enclosed within the autophagosome. Autophagosomes subsequently fuse with lysosomes, to become autolysosomes, the contents of which are then degraded. The degradation products are then transported to the cytosol for reuse by the cell.

The second process is non-canonical autophagy [24,46–48]. This pathway has the same basic structure and function as macroautophagy, but not all the Atg proteins are required to form a functional autophagosome. Moreover, the direct recruitment of a set of Atg proteins to preexisting membranes has been described [49].
Figure 2. A simplified overview (a modified schema from [38,50,51] of LC3-associated phagocytosis (LAP) and canonical autophagy. (a) LAP is triggered by Toll-like receptors (TLRs) and other pattern recognition receptors (PRRs) in response to microorganisms, such as bacteria, that are taken up by phagocytosis or that have actively invaded non-phagocytic cells. LAP requires a subset of autophagy genes for the labelling of phagosomes with LC3 (Atg8), which promotes their lysosomal delivery and the efficient killing of vesicular pathogens; (b) Damage of the limiting membrane of the pathogen-containing vesicle, either accidental or caused by pathogens attempting to escape from the vesicle, exposes the cytosol to glycans previously hidden inside the vesicle; (c) Cytosol-accessible glycans are detected by galectin-8 (danger receptor), which, by recruiting the cargo receptor NDP52 (nuclear dot protein 52), triggers autophagy; (d) Pathogens having escaped galectin-8-induced autophagy are met by another layer of PRRs in the cytosol such as NLR, and a yet-to-be-identified E3 ubiquitin ligase causes the ubiquitin-coating of invading bacteria. It remains to be established whether this ligase only targets membrane-associated or also free-floating bacteria, whether it is a PRR, and also whether its substrate is of bacterial [52] or host origin such as LRSAM1 [53] or WWP1 [54]; (e) A dominant pathway in the autophagic capture of bacteria such as Salmonella relies on tagging bacteria with a poly-ubiquitin coat, which is then bound by three apparently non-redundant ubiquitin binding autophagy adaptors, NDP52, p62 and optineurin [55–58]. As pointed out by Mostowy et al. [59], the recruitment of p62 and NDP52 to Shigella is interdependent. These adaptors subsequently recruit specific autophagic machinery components, such as the LC3/Atg8 family proteins, triggering the autophagic cascade and autophagosome formation (initiation, elongation and closure).
The third process is LC3-associated phagocytosis (LAP), which involves the direct recruitment of LC3 to single-membrane phagosomes [25]. LAP is initiated following infection with several bacterial pathogens, including *Escherichia coli* [60], *Salmonella serovar Typhimurium* [61], *Burkholderia pseudomallei* [62] and *Listeria monocytogenes* [63]. It requires some of the molecular machinery used for autophagosome formation, but the initiating ULK1 complex is dispensable [64]. In the context of bacterial infection, LAP is thought to ensure the rapid clearance of bacterial pathogens, by increasing phagocytosis and bacterial killing, as first demonstrated for *E. coli* [60]. Both autophagosomes and phagosomes undergoing LAP have LC3 in their membranes. One standard way of assessing autophagy involves determining the colocalization of bacteria with LC3, which is almost invariably detected as GFP-LC3 puncta. However, there is no readily applicable, simple technique for differentiating between the puncta corresponding to phagosomes and those corresponding to autophagosomes. The role of LAP in bacterial infections may therefore have been underestimated. Electron microscopy is the method of choice for distinguishing between single-membrane (phagosome) and double-membrane (autophagosome) compartments [65], but it is not always used by investigators. Figure 2 shows a simplified overview of LC3-associated phagocytosis (LAP) and canonical autophagy.

As pointed out by Lippai and Löw (2014) [66], the best known way to distinguish between the different cytoplasmic components destined for engulfment is to target properly labeled cargos to the inner surface of the growing phagophore. Precise delivery is generally ensured by interaction of the adaptor with both the membrane-anchored form of LC3, and the principal targets, which are mostly polyubiquitinylated. The recognition of ubiquitinylated proteins during autophagy is mediated by ubiquitin receptors interacting with ubiquitin-binding domains. p62, also known as SQSTM1, the first protein reported to have such an adaptor function [67], possesses a C-terminal ubiquitin-binding domain (UBA) [68] and a short LIR (LC3-interacting region) sequence responsible for LC3 interaction [67]. Ubiquitin-binding adaptor proteins, such as p62, NDP52 (nuclear dot protein 52) and optineurin, target many bacteria. p62 is required for the aggregation of ubiquitinylated proteins and plays a major role in their autophagic clearance [69,70]. Optineurin and NDP52 have recently been described as xenophagy receptors, making use of the autophagic machinery to eliminate ubiquitinylated intracellular pathogens [71]. The role of p62 in the regulation of autophagy remains a matter of debate. It has been suggested that it promotes mTORC1 activation through involvement in its translocation to the lysosomal surface. Therefore, p62 reduction, like mTORC1 inactivation, may activate autophagy [72]. Moreover, p62 and NDP52 target intracytosolic *Shigella* to different autophagy pathways [59], and p62 also targets *Salmonella* [55,73]. One of the autophagy pathways to which *Shigella* is targeted by p62 and NDP52 is dependent on septin and actin [59]. Intracytosolic *Listeria* avoids recognition for autophagy by expressing ActA, a bacterial effector required for actin polymerization; p62 or NDP52 targets the *Listeria* ActA mutant to an autophagy pathway independent of septin and actin [59].

As highlighted by Sorbara and Girardin [74], it remains unclear how infected cells direct the phagophore to bacteria either free in the cytosol or confined to a vacuole without targeting other cellular constituents, such as organelles. This aspect is the subject of active investigations in the field of xenophagy. However, three other molecular mechanisms, in addition to ubiquitination, are known to confer bacterial targeting during xenophagy. These mechanisms involve: (i) Nod proteins; (ii) a galectin-dependent pathway and (iii) diacylglycerol (DAG). The Nod-like receptor (NLR) proteins Nod1 and Nod2 are cytosolic proteins that detect specific fragments derived from bacterial peptidoglycan and
Toxins 2015, 7 2924

initiate pro-inflammatory signaling (NF-κB and MAP kinase pathways) [75]. Moreover, Nod1/2 interacts with the autophagy protein Atg16L1, driving recruitment of the autophagic machinery at the site of bacterial entry [76]. However, it is unclear whether Nod1/2 can detect bacteria, such as *Shigella* or *Listeria*, when they are free in the cytosol. Galectin proteins, such as galectin-8/3/9, are glycan-binding lectin proteins that are found in the cytosol and accumulate at sites of membrane damage due to *Salmonella* [77]. NDP52 is recruited to the *Salmonella*-containing vacuole (SCV) by galectin-8, through a mechanism different from the ubiquitin-mediated recruitment of NDP52 to the SCV [77]. Galectin proteins may be considered to be crucial sensors of the danger signals initiated at the damaged membrane by the exposure of glycans to the cytosol, these molecules normally being exposed to the vesicle lumen.

The early accumulation of DAG around the SCV has been observed in *Salmonella*-infected cells [78] and the inhibition of DAG formation by pharmacological or genetic approaches results in the inhibition of bacterial autophagy [79]. The DAG-dependent and ubiquitin-dependent pathways of xenophagy, with targeting to the SCV, seem to be independent [79]. However, possible interdependence with other pathways remains to be assessed: see a review in [74]. It remains unclear whether DAG-dependent autophagy is a bacterial or host-initiated process [78].

One of the main features of autophagy is the dynamic rearrangement of cell membrane structures through multiple membrane fusion events. Soluble *N*-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) are known to play a key role in docking and the fusion of intracellular membranes. SNARE proteins include the vesicle-associated membrane proteins (VAMPs), which have glutamine as the central amino acid of the SNARE motif. VAMP3 and VAMP7 are thought to be involved in the fusion of autophagosomes and lysosomes. VAMP7 may be involved in phagosome formation during *Helicobacter pylori* infection, whereas VAMP3 is involved in phagosome maturation following *Mycobacterium tuberculosis* infection. *Yersinia pseudotuberculosis* has been shown to survive in murine bone marrow-derived macrophages (BMDMs), by hijacking autophagy and impairing autophagosome acidification: Atg5 knockdown facilitates *Yersinia* degradation [80]. This finding is consistent with the hypothesis that autophagy provides a replicative niche for this pathogen [80].

Numerous bacterial pathogens produce toxins that can interfere with host defense pathways. Interplay between autophagy and the regulation of pathogen replication is thought to occur [50]. Autophagy is an important cellular defense mechanism and a means of generating antigenic peptides for major histocompatibility complex (MHC) presentation. During bacterial infection, host cells can initiate autophagy to eliminate intracellular pathogens and/or toxins. The system may be more complex, involving the generation of inflammatory mediators, which may activate autophagy [81,82]. However, this process can also be exploited by microbes for survival and replication, potentially leading to host cell death [39].

The question of the role of bacterial toxins in triggering and regulating autophagy is considered in more detail below.
3. Are the Different Interactions of Autophagy and Bacterial Toxins Involved in Bacterial Pathogenesis?

There is evidence to suggest that the autophagy pathway plays a key role in innate immune defenses against intracellular pathogens (autophagy against intracellular pathogens is also called xenophagy). Antibacterial autophagy involves the selective recognition of intracellular bacteria and their targeting of the autophagy machinery for degradation [83].

3.1. Lipopolysaccharides

Lipopolysaccharides (LPS) are among the most immunostimulatory components of the outer membrane of Gram-negative bacteria. LPS signals through the Toll-like receptor 4 (TLR4), inducing potent inflammatory responses and septic shock [84]. Autophagy has been shown to be involved in the secretion of proinflammatory cytokines in mice, through deletion of the gene encoding the autophagy protein Atg16L1, which triggers the production of large amounts of interleukin 1β (IL-1β) and IL-18 in response to LPS and other pathogen-associated molecular patterns (PAMPs) [85]. Atg16L1 has been identified as an Atg5-binding protein required for autophagy principally to regulate the location of the Atg12-Atg5 conjugate and for LC3 conjugation to phosphatidylethanolamine. Moreover, the depletion of autophagy proteins, such as LC3 and beclin-1, enhances the ATP-activation of caspase-1 and the secretion of IL-1β and IL-18 in a model of LPS-primed macrophages, and increases susceptibility to LPS-induced septic shock in vivo, in an experimental model of sepsis [86].

The autophagic machinery can be activated upon PAMP detection, by the cognate PRRs (pattern recognition receptors) [87]. This is an important barrier, particularly as there have been reports of an inability to detect macroautophagy downstream from TLR stimulation [85]. PRR signaling in autophagy may involve the complex reportedly formed between TLR adaptors (MyD88 and TRIF) and Beclin 1, and changes in the interaction of the antiapoptotic protein Bcl-2 with Beclin 1 upon TLR stimulation [88], akin to the Bcl-2-Beclin 1 interactions observed during the activation of autophagy by non-immunological signals [89].

Autophagy can also be regulated by reactive oxygen species (ROS) [90]. For example, the ROS produced by NADPH oxidase downstream from stimulation of the TLR or the Fcγ receptor in phagocytes has been shown to activate autophagy [61]. As previously described, LC3-II appears on phagosomes (LAP) without the formation of conventional double membranes, shortly after particle uptake, and the costimulation of TLRs by particles was responsible for initially drawing attention to the unconventional roles of Atg proteins [60]. However, the coactivation of NADPH oxidase and ROS production during the phagocytosis of opsonized or PAMP-laden particles may, in essence, mirror the observed induction of autophagy by ROS produced by mitochondria in response to starvation stimuli [90]. These events may best be understood within the concept of APMA (autophagic macrophage activation), a set of linked events in macrophages including connections between ROS production and autophagy. One recent review highlighted the crucial role of autophagy in inflammation and apoptosis in diseases [91]. The key role of mTOR in cellular metabolism is well known and its emerging role in antibacterial immunity is complex [92]. Several reports have linked immunity and metabolism [93,94]. The relationship between TLR signaling and mTOR activity was established in studies investigating the...
stimulation of innate immune cells with LPS. Rapamycin, a well-known inhibitor of mTOR activity, inhibits LPS-induced macrophage activation, and targets of mTOR signaling have been shown to be stimulated by LPS [95,96]. Two mTOR complexes have been identified: mTOR complex 1 (mTORC1), containing the Raptor protein and serving as the main mediator of metabolic homeostasis, and mTORC2 containing the Rictor protein and shown to act as the kinase complex for AKT [97]. Subsequent studies provided more insight into the mechanisms involved [98,99], with mTOR signaling described as regulated principally by TLRs, through two major pathways: an NF-κB-dependent pathway and a PI3K/AKT-dependent pathway. In the NF-κB pathway, the IKKβ protein, which is activated downstream from TLR signaling [100], may contribute to mTOR activation through the phosphorylation of tuberous sclerosis complex (TSC) 1, resulting in its inactivation. One recent study [101] described the reduction, by IKKβ inhibitors, of the LPS-induced phosphorylation of S6K1, a downstream target of mTOR, in MCF-7 cells. The second major link between TLR and mTOR signaling involves the PI3K/AKT pathway. LPS has been shown to induce TSC2 phosphorylation, which inactivates the TSC1/TSC2 heterodimer, leading to mTOR activation [102], and AKT inhibitors, which blunt TSC2 phosphorylation [103]. There is genetic evidence to suggest that the PI3K pathway acts as a critical negative regulator of the pro-inflammatory response, but the outcome of PI3K activation downstream from immune receptors depends on the type of cell activated (reviewed in [100]). As these data were obtained for different cell types, in vivo experiments are required to confirm the involvement of these pathways.

Nod-like receptors constitute another type of PAMP detector: Nod1 detects moieties containing D-glutamyl-meso-diaminopimelic acid from Gram-negative bacteria [104], and Nod2 detects muramyl dipeptides from the peptidoglycans of certain bacteria [105]. The role of Nod-like receptors in mTOR signaling has received much less attention than that of TLRs (reviewed in [92,106]). However, some of the available data suggest that the intracellular sensors Nod1 and Nod2 are critical for the autophagic response to invasive bacteria. Nod1 and Nod2 recruit the autophagy protein ATG16L1 to the plasma membrane at the site of bacterial entry [76].

The outcome of LPS stimulation depends on the cell type studied and the orchestration and fine tuning of an ongoing immune response, with pleiotropic roles for the various molecular actors involved. Intracellular pathogens have developed virulence factors strongly involved in pathogenicity, such as toxins, to help them to survive after entering eukaryotic cells.

3.2. Bacterial Pore-Forming Toxins (PFTs)

Pore-forming toxins (PFTs) are the most common class of bacterial protein toxins, and are important bacterial virulence factors [107]. They are secreted by the pathogens in a water-soluble form that binds to the target cell, generally leading to multimerization to form an amphipathic structure that inserts itself into the target cell membrane to form a pore. PFTs are classified according to the type of structure they use to insert into the lipid bilayer upon pore formation: α-PFTs cross the membrane as α-helices, whereas β-PFTs do so as β-sheets. The pore-forming colicins secreted by Escherichia coli are representative members of the α-PFT family [108]. A number of similar proteins that do not fully qualify as PFTs should also be mentioned. The most prominent of these proteins include the translocation domains of certain non-pore-forming toxins. In these so-called “AB” toxins, the B subunit is responsible for binding
to the target cell and translocation of the A subunit into the cytoplasm. The A subunit has enzymatic activity. Examples include the diphtheria toxin, the translocation domain of which resembles colicins, and anthrax toxin, the B subunit of which forms a heptameric transmembrane channel similar to aerolysin, and the staphylococcal α-toxin channel. The B subunits of AB toxins do not insert into the membrane of target cells because they require an acidic environment. Anthrax toxin, secreted by *Bacillus anthracis*, consists of three protein exotoxins called the edema factor (EF), the lethal factor (LF) and the protective antigen (PA). Binary combinations that include EF+PA, referred to as the edema toxin (ET) and LF+PA, referred to as the lethal toxin (LT), are toxic ([109]). As described by Parker et al. [110], the two moieties required for toxicity are named A and B, by analogy to other toxins in which the A moiety bears the toxic enzymatic activity and the B moiety binds to the surface of the target cell and delivers the A moiety into the cytosol PA mediates translocation of the two alternative A moieties, LF and EF, into the cytosol. EF is an adenylate cyclase, which will be described in the next section. LF is a zinc metalloprotease, the canonical substrates of which are mitogen-activated protein kinase kinases, which it inactivates [111], thereby disrupting signaling pathways in host cells. As reported by Agarwal and Bishai, 2009 [112], LF can induce autophagy in mammalian cells, presumably to enhance the clearance of bacteria from the cytoplasm by diverting toxins to the autophagosome, where they are degraded, after lysosomal fusion.

Cytolysin toxin (VCC), a pore-forming toxin from *Vibrio cholerae* [113], causes extensive vacuolation in epithelial cells. The relationship between the vacuolation caused by VCC and the autophagic pathway was investigated and the authors showed that treating cells with VCC increased the punctate distribution of LC3, which was colocalized with VCC-induced vacuoles, demonstrating the interaction of large vacuoles with autophagic vesicles. Electron microscopy confirmed that the vacuoles induced by VCC had the hallmarks of autophagosomes. Interestingly, the inhibition of autophagy leads to lower cell survival in the presence of VCC. VCC also fails to induce vacuolization in Atg5−/− cells, and these cells have strongly impaired survival responses to this toxin. Thus, autophagy acts as a cellular defense pathway against secreted bacterial toxins, but it remains unclear whether these toxins have a dynamic relationship with autophagy.

*Staphylococcus aureus* secretes a number of pore-forming toxins, such as α-toxin, which oligomerizes on binding to a target cell. The resulting oligomers then insert into lipid bilayers to form pores [110]. Pore-forming toxins induce a large decrease in intracellular ATP levels [114–118]. As reported by Kloft and colleagues [119], PFTs, such as *S. aureus* α-toxin, *V. cholerae* cytolysin (VCC), streptolysin O and *E. coli* hemolysin, induce the phosphorylation of AMPK in epithelial cells. Morphological features, such as multivesicular bodies and vesicles delineated by double membranes, have provided evidence for the induction of autophagy by PFTs [120]. Studies of several bacterial species, such as *Streptococcus pyogenes*, *Listeria monocytogenes*, *Shigella flexneri*, *Salmonella enterica* and *S. aureus* [121–124], have shown that selective autophagy can be induced by membrane damage and/or PFTs. Selective autophagy has been shown to correlate with the ability of intracellular *L. monocytogenes* and *S. aureus* to produce a PFT, listeriolysin O (LLO) and α-toxin, respectively [119,123,125]. As described earlier in another model of autophagy (a nitrogen starvation-induced autophagy in yeast) [126], plasma membrane perforation triggers a starvation response and autophagy involving the eIF2α-kinase GCN2 [119,120]. GCN2 (general control, non-derepressible 2) also called eIF2α-kinase 4, acts as a nutrient sensor. The phosphorylation of eIF2α-kinase causes a general blockade of translation, but some genes are exempt
from this process and are overexpressed. This so-called “integrated stress response” is thought to prevent the accumulation of unfolded proteins during stress, to conserve energy and to reprogram gene expression [119].

As recently reported [127], the cellular receptor A disintegrin and metalloprotease 10 (ADAM10) has been identified as the α-toxin receptor. α-toxin targets both endothelial cells and epithelial cells, upregulating the enzymatic activity of ADAM10 and culminating in disruption of the tissue barrier in vitro and in vivo [128,129]. Maurer and colleagues (2015) found that stronger ADAM10 expression in autophagy-deficient mice exacerbates S. aureus infection [130]. This finding confirms the vital nature of the interaction of the toxin-ADAM10 complex in bacterial pathogenesis. Moreover, Atg16L1 deletion in endothelial cells increases lethality in vivo and this effect is dependent on α-toxin [131].

Several authors investigating the interaction of bacterial toxins and autophagic process have shown that bacterial toxins provide support for bacterial replication. It has been known for some time [132] that Listeria monocytogenes, a Gram-positive bacterium, survives within cells by producing listeriolysin (LLO), a pore-forming cytotoxin allowing it to escape from phagosomes.

Listeria, probably with low levels of LLO expression [37], is targeted by the LAP pathway via diacylglycerol enrichment and downstream reactive oxygen species production, to establish spacious Listeria-containing phagosomes (SLAPs), which serve as intracellular niches for the bacterium [63]. LLO is known to uncouple the pH gradients of the primary phagosome by creating small pores in the phagosomal membrane [133]. As reported by Birmingham et al. [134], LLO, which is sufficient and necessary for SLAP formation, may uncouple pH gradients across SLAP membranes. These authors hypothesized that autophagy might be involved in SLAP formation, through the targeting of damaged phagosomes to prevent bacterial escape into the cytosol. Differences in LLO activity seemed to result in different fates for L. monocytogenes within host cells [134]. At high LLO concentrations, the bacteria escape rapidly from the phagosomes and L. monocytogenes grows rapidly in the cytosol. At low LLO concentrations, phagosomes might mature into SLAPs, leading to slow bacterial growth in vacuoles. According to this hypothesis [134], the host cell preserves its viability by preventing bacterial colonization of the cytosol, but is unable to eradicate the pathogen. Lafont’s group [135] recently published a paper on LC3-associated pathways. They reported that the phagocytosis of TLRs in murine macrophages triggered LC3 recruitment to phagosomes: Listeria monocytogenes expressing low levels of LLO is not prone to phagosome escape and resides in single-membrane, LC-3 positive, spacious Listeria-containing phagosomes. Gupta et al. [136] showed that the clearance of Listeria monocytogenes from macrophages required interferon regulatory factor 8 (IRF8)-dependent activation of autophagy genes, followed by the autophagic capture and degradation of Listeria antigens.

VacA, a key toxin in H. pylori pathogenesis [137] that induces the formation of large vacuoles in intoxicated cells, is secreted as a monomer via a type IV autotransporter. It then inserts into the host cell membrane and assembles into dodecamer structures. VacA oligomers form chloride-selective membrane channels, which are essential for many of the cytotoxic effects in intoxicated cells. The 88-kD monomer can be cleaved into two subunits, p33 and p55. Structural data suggest that p33 forms the central pore, with p55 protruding outward into the lipid bilayer.

VacA can impair autophagic flux [138]. Conversely, autophagy can promote VacA degradation at early stages of infection, as shown by the enhanced accumulation of VacA in Atg5-deficient mouse
embryonic fibroblasts (MEFs) [138]. Early VacA degradation by autophagy may limit the ability of VacA to access the cellular compartments/cofactors required to inhibit autophagic flux.

*Serratia marcescens*, a Gram-negative bacterium that is an opportunistic pathogen in humans, produces numerous exotoxins, including the Sh1A pore-forming toxin. One very recent study [139] has shown that this toxin can elicit an autophagic response in host epithelial cells, highlighting its functional importance in the life cycle of *Serratia*. However, the link between autophagy and pathogenicity has not been clearly demonstrated and further in vivo experiments are required to confirm these observations.

Yu et al. [140] showed that autophagy facilitates *Salmonella* replication in the cytosol of HeLa cells. *Salmonella enterica* serovar *Typhimurium* is a facultative intracellular pathogen that contains two type III secretion systems (T3SSs) encoded by *Salmonella* pathogenicity islands (SPI-1 and -2). These T3SSs are necessary for *Salmonella* pathogenicity, as they deliver bacterial proteins to the host cell cytosol for the manipulation of various host cell pathways. The T3SS apparatus proteins InvA and SipB (a pore-forming toxin) and the effector SopB are required for the association of *Salmonella* with autophagosomes for replication in HeLa cells. These results challenge previous reports that p62 and autophagy protect host cells against *Salmonella* infection [55,124,141]. Through its pore-forming activity, SipB may damage *Salmonella*-containing vacuoles (SCV), allowing *Salmonella* to enter the host cell cytosol, where it can obtain access to the autophagy machinery. Further studies are required to account for these discrepancies and to decipher the complexity of the different interactions between intracellular bacteria, bacterial toxins and autophagy pathways.

### 3.3. Bacterial Adenylate Cyclases

Many bacterial pathogens have evolved mechanisms for exploiting the regulatory functions of cAMP to suppress immune responses [142]. For example, *Bacillus anthracis*, *Bordetella pertussis*, *Pseudomonas aeruginosa*, *Yersinia pestis* and *Mycobacterium tuberculosis* produce adenylate cyclase toxins that increase intracellular cAMP levels in host cells. *Staphylococcus aureus* can synthesize adenosine, to increase cAMP levels in host cells through the activation of G-protein coupled adenosine receptors [143]. Most immunosuppressive phenotypes associated with toxins that increase cAMP levels have been attributed to the actions of either EPAC or PKA. The authors of this study showed that bacterial toxins that increase cAMP levels inhibit several types of autophagy, including antibacterial autophagy, in host cells. Two different bacterial toxins inducing increases in cAMP levels have been studied in particular detail: (i) edema toxin (ET) from *Bacillus anthracis*, formed from the edema factor (EF) and the protective antigen (PA), PA is required for the delivery of EF to the mammalian cytosol. EF is a calmodulin-dependent adenylate cyclase toxin (AC) that directly increases intracellular cAMP levels; (ii) cholera toxin (CT) from *Vibrio cholerae*, consisting of a component that functions as an ADP ribosyltransferase capable of increasing intracellular cAMP levels in an indirect manner. By contrast, both *B. anthracis* and *V. cholerae* express a second toxin, including the metalloprotease lethal factor (LF) and a PFT cytolysin (VCC) respectively, shown to modulate autophagy in target cells [113]. Moreover, the toxin factors secreted by bacteria, such EF and LF from *Bacillus anthracis*, can cooperate to suppress innate immune responses [144]. LC3 processing does not seem to be affected, suggesting that the toxins that increase cAMP levels disrupt a downstream step in autophagosome formation.
Table 1 shows examples of different factors potentially involved in the inhibition of autophagy initiation signaling, such as edema factor toxin from *B. anthracis* and cholera toxin from *Vibrio cholerae* [145] (lethal factors from *B. anthracis* and cytolysin from *V. cholerae* are not mentioned) and an unknown factor from *S. enterica* serovar *Typhimurium* that may affect the mTOR complex [146]. Some bacteria interfere directly with the activity of components of the autophagy pathways, for example, VirA from *Shigella flexneri*, which inhibits RAB1 in the host cell [147]. Moreover, some bacterial factors, such as IcsB from *S. flexneri* and ActA/InlK (an internalin-like protein) from *L. monocytogenes*, enable the bacteria to evade autophagy recognition by masking the bacterial surface. IcsB has been shown to block bacterial engulfment by autophagosomes by camouflaging the bacterial surface protein VirG and inhibiting its interaction with Atg5 [148]. *Listeria monocytogenes* and *Shigella flexneri* evade autophagy by escaping from the vacuole by using factors (LLO, PI-PLC and IpaB) facilitating vacuole disruption [31,149–151]. Some bacteria escape autophagy by as yet undetermined mechanisms. For example, *Burkholderia pseudomallei* escapes autophagy by using various effectors [62,152] and *Francisella tularensis* does so using DipA [153,154].

**Table 1.** Examples of factors involved in the interplay between bacteria and autophagy, according to Huang & Brumell [155] and Asrat et al. [156].

| Bacterium                  | Bacterial factors          | Host factors               | References |
|----------------------------|----------------------------|----------------------------|------------|
| *Bacillus anthracis*       | Edema factor toxin         | cAMP                       | [145]      |
| *Vibrio cholerae*          | Cholera toxin              | cAMP                       | [145]      |
| *Salmonella enterica*      | Unknown                    | mTOR, RAG GTPases          | [146]      |
| *serovar* *Typhimurium*    |                            |                            |            |

**Directly interfering with the activity of autophagy components**

| Bacterium                  | Bacterial factors          | Host factors               | References |
|----------------------------|----------------------------|----------------------------|------------|
| *Shigella flexneri*        | VirA                       | RAB1                       | [147]      |
| *Listeria monocytogenes*   | IcsB                       | Atg5 and septins           | [59]       |
|                            | ActA and InlK              | MVP and host factors that bind ActA | [157,158] |

**Evading autophagy recognition by masking the bacterial surface**

| Bacterium                  | Bacterial factors          | Host factors               | References |
|----------------------------|----------------------------|----------------------------|------------|
| *Listeria monocytogenes*   | LLO (cholesterol-dependent| Membrane pore formation    | [149]      |
|                            | cytolysin                  |                            |            |
| *Listeria monocytogenes*   | PI-PLC (phosphatidylinositol-| Facilitate vacuole disruption for escape | [31,150] |
|                            | specific phospholipase)    |                            |            |
| *Shigella flexneri*        | IpaB (membrane pore formation) | Host cell invasion, membrane disruption and escape from the SCV | [31,151] |

**Escaping autophagy by unclear mechanisms**

| Bacterium                  | Bacterial factors          | Host factors               | References |
|----------------------------|----------------------------|----------------------------|------------|
| *Burkholderia pseudomallei*| T3SS3 effector BopA and    | Unknown                    | [62,152]   |
|                            | translocator BipD, T3SS1 ATPase |                            |            |
|                            | encoded by bpscN           |                            |            |
| *Francisella tularensis*   | DipA                       | Unknown                    | [153,154]  |

As previously described, other pathogens, such as *S. aureus*, can synthesize adenosine, which seems to be required for escape from phagocytic clearance [143]. Extracellular adenosine can increase intracellular cAMP levels by activating cell-surface adenosine receptors [159]. The inhibition of autophagy by an increase in cAMP levels after the internalization of *S. aureus* may be involved in the
escape mechanism, but this remains to be demonstrated. As reported in recent studies on yeast [160–162], PKA-specific phosphorylation sites have been identified on two critical autophagy proteins: Atg1 and Atg13. The PKA-mediated phosphorylation of these factors impaired the localization of Atg1 and Atg13 to the phagophore assembly site, resulting in an autophagy defect. The possible phosphorylation of mammalian homologs of Atg1 and Atg13 by PKA remains to be investigated, and further studies are required to determine how the cAMP/PKA pathway affects the regulation of autophagy and its consequences for immunity in mammals. One particularly interesting study [163] showed that ET and CT induced a strong increase in cAMP levels in the perinuclear region. The authors of this study highlighted the importance of compartmentalization in cAMP-dependent signaling in many cell types. By contrast, they also showed that *Bordetella pertussis* adenylate toxin and forskolin (a pharmacological reagent used to increase intracellular cAMP levels) triggered an increase in cAMP concentration just below the plasma membrane [163]. ET and CT induce massive, long-lasting cAMP synthesis and PKA hyperactivation, triggering CREB phosphorylation and negative feedback activity.

Nevertheless, the published findings for this study suggest that the inhibition of autophagy by toxins increasing cAMP concentration is of immediate benefit to the pathogen, as it blocks xenophagy, with the internalized bacteria thus avoiding degradation in the lysosome. Autophagy is required for the generation of antimicrobial peptides in lysosomes [164,165]. However, the precise role of bacterially induced autophagy inhibition in virulence remains incompletely understood, although a microarray analysis of *Francisella tularensis*-infected macrophages revealed that several autophagy genes were downregulated [166]. Nevertheless, *in vivo* experiments are required to affirm this hypothesis.

### 3.4. Other Virulence Factors

Microbial pathogens that successfully parasitize eukaryotic cells (*i.e.*, intracellular pathogens) have evolved in the setting of selective pressures imposed by cellular autophagy as a pathway central to innate and adaptive immunity. It is therefore unsurprising that microbes have developed several strategies for avoiding autophagolysosomal degradation and/or decreasing the autophagy-dependent activation of host immune responses. Researchers are beginning to decipher these molecular strategies and their potential roles in microbial pathogenesis, although our understanding of these aspects remains rudimentary in most cases.

What appears more likely, at least based on the limited research to date, is that microbial adaptations suppressing the induction of autophagy may target some of the more general (*i.e.*, not pathogen-specific) signaling pathways involved in the up- or downregulation of autophagy.

Another strategy employed by intracellular bacteria to escape the undesirable fate of lysosomal destruction is avoidance of capture by the autophagosome. Bacteria residing in phagosomes or other vacuolar compartments may seek to avoid lysosomal maturation, but the avoidance of autophagic capture may be particularly important for intracellular bacterial pathogens that escape into the cytoplasm. The evasion of autophagic capture has been described for at least three different intracytoplasmic bacteria: *Shigella flexneri*, *Listeria monocytogenes*, and *Burkholderia pseudomallei*. The first example to be described was the classic case, that of the escape of *Shigella* from autophagy. This escape seems to involve a particularly intriguing mechanism [148]. *Shigella* possesses a surface protein, VirG, required for actin-based motility. This protein binds to the autophagy protein Atg5, thereby targeting *Shigella* to
the autophagosome. However, the bacterial T3SS effector, IcsB, binds competitively to Atg5, thereby hiding its own target molecule, VirG, and preventing autophagic capture. Together with the suppression of autophagosomal fusion with lysosomes and/or the acidification of pathogen-containing compartments, the bacterial autophagosomal-like compartments may enable the bacteria to persist in a nonacidic compartment. The enhanced pathogenicity of *L. monocytogenes* in mice with a macrophage-specific deletion of *Atg5* [167] demonstrates that *Atg5* expression in phagocytic cells is essential for cellular immunity to intracellular pathogens. In addition to shielding bacteria from the endolysosomal pathway, it has also been suggested that the localization of bacteria to LC3-positive compartments may allow cytoplasmic bacteria to regain access to the endocytic compartment, to promote bacterial egress through exocytosis (*i.e.*, during *Francisella* infection) [154]. Other strategies also exist. For example, a streptococcal cysteine protease, SpeB, plays a critical role in the avoidance of ubiquitylation and recognition by the host autophagy marker LC3 and the ubiquitin-LC3 adaptor proteins NDP52, p62 and NRB1 [168].

Bacterial toxins and some virulence factors seem to interact with the autophagy machinery to allow the expression of bacterial pathogenicity. Several proteins involved in autophagic mechanisms, such as Atg5 and Atg16L1, seem to play a major role, as their deletion enhances pathogenicity [131,148,167]. As reported by Mostowy & Cossart in 2012 [124], autophagy controls the fate of a number of intracellular bacteria, including *Listeria, Shigella, Francisella, Salmonella* and *Mycobacterium*. By contrast, other bacterial pathogens, such as *Legionella, Coxiella, Yersinia, Brucella and Staphylococcus*, benefit from autophagy pathways and may subvert the autophagy machinery to favor the infection process. These alternative outcomes highlight the molecular complexity underlying bacterial autophagy, and suggest possible difficulties in the therapeutic modulation of autophagy to resolve bacterial infection.

However, here we will analyze pharmacological strategies for enhancing or restoring autophagy processes to limit bacterial pathogenicity and to improve bacterial clearance.

4. What Therapeutic Potential Does the Targeting of Molecules Involved in the Autophagy Machinery Have for the Resolution of Bacterial Infections?

Here, we will focus on FDA-approved drugs and nutritional supplements, such as antioxidants and vitamins, already used in humans and likely to increase autophagy, which could therefore potentially be used to limit toxin effects, to prevent increases in bacterial numbers and to facilitate bacterial clearance (the contribution of autophagy upregulation to the therapeutic effects of these drugs for their currently approved clinical indications is unknown). Moreover, non-pharmacological interventions, such as caloric restriction and regular exercise, induce autophagy and may improve overall health [169,170].

In this review, antibodies able to block bacterial toxins specifically are not discussed, despite our department’s development of monoclonal antibodies against anthrax toxins [171,172]. This strategy is very interesting but it requires the development of specific antibodies against each toxin, which may be very challenging. The development of specific inhibitors of enzyme activity for a given toxin, such as LT, is another strategy, involving the high-throughput screening of potential inhibitors [173]. It could be interesting to target an enzyme used by numerous bacteria, such as a specific inhibitor of bacterial adenylate cyclase. Finally, the targeting of bacterial toxins involved in autophagy induction might be a more interesting therapeutic approach than targeting proteins involved in the regulation of autophagy,
but it may be difficult to find molecules able to counteract different bacterial toxins or to develop a specific anti-toxin molecule, which would be very expensive. One key challenge is the identification of new specific inducers of autophagy with fewer unwanted side effects than for available drugs. For the identification of new autophagy-inducing molecules, chemical screens can be performed, based on measurements of the fluorescence of autophagosomes (GFP-LC3-positive puncta) by live-cell imaging methods [174], FACS-based measurements of total levels of LC3 as readouts of autophagy [175–177], high-throughput screening approaches for identifying new regulators [178] or biochemical methods for the analysis of LC3 and p62 [179]. Proteomic mapping methods, such as spatially restricted enzymatic tagging, in living cells may be useful for the identification of autophagy-specific regulatory steps [180]. For example, as suggested by Levine et al. [181] targeting the kinase involved in phosphorylation of the autophagy receptor optineurin could enhance autophagic substrate clearance, including the clearance of ubiquitin-coated bacteria [182].

A synergistic strategy using a combination of antibiotic therapy and molecules targeting inflammatory processes was investigated by Popov et al. [183], who showed that the outcome of antibiotic treatment in a murine anthrax model could be substantially improved by combined administration of the caspase-1/4 inhibitor YVAD and the A3R agonist Cl-IB-MECA (chloro-6-[(3-iodophenyl)methyl]amino]-9H-purin-9-yl]-1-deoxy-N-methyl-beta-D-ribofuranuronamide). The overall effect of this treatment is the inhibition of interleukin-1β-induced inflammation and activation of adenosine type-3 receptors (A3Rs). Treatments combining these molecules with ciprofloxacin resulted in up to 90% synergistic protection. All the untreated mice died, and antibiotic treatment alone protected only 30% of the animals. The authors of this study suggested that A3R activation inhibited the toxin-induced increase in intracellular cAMP levels, but no link to autophagy was described; this strategy is based on synergy with antibiotic treatment. Recent papers have described pharmacological agents targeting autophagy [181,184,185]. We focus here on FDA-approved drugs and nutritional compounds able to modulate autophagy. However, these products generally have pleiotropic actions, making it difficult to determine the contribution of the induction of autophagy to their therapeutic effects in patients. Preclinical studies [181] have demonstrated that some autophagy-inducing agents fail to induce their beneficial effects in host organisms lacking autophagy genes. Autophagy enhancement has been reported to be useful in preclinical models of diseases: mTOR inhibitors in neurodegenerative diseases [186], tyrosine kinase inhibitors in diabetic nephropathy [187] and neurodegenerative diseases [188–190], carbamazepine in α1-antitrypsin deficiency [191], trifluoperazine in Salmonella infection [192] and statins in Mycobacterium tuberculosis infection [193]. It is unknown whether autophagy upregulation contributes to the therapeutic effects of these agents for their currently approved clinical indications. For acute infectious diseases, the non-autophagy-inducing actions may be tolerable if they are mild or apparent at doses substantially higher than those required to enhance autophagy. As shown in Table 2, currently available autophagy-inducing drugs and nutritional compounds can be grouped into four classes [2]:

---

**Table 2:**

| Autophagy-Inducing Drugs and Nutritional Compounds |
|--------------------------------------------------|
| Ciprofloxacin                                    |
| YVAD                                             |
| Cl-IB-MECA                                       |
| Cocaine                                         |
**Table 2.** Selected FDA-approved drugs, pharmacological agents and nutritional compounds that modulate autophagy.

| Autophagy inducers | Mechanism of action                                                                                                                                                                                                 | References     |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|
| FDA-approved-drugs |                                                                                                                                                                                                                     |                |
| Rapamycin          | Induces autophagy by inhibiting mTORC1                                                                                                                                                                               | [194–196]      |
| Metformin          | Upregulates AMPK, which promotes autophagy by inducing ULK1 phosphorylation                                                                                                                                              | [197,198]      |
| Isoniazid          | Activates autophagy flux, oxidative stress and upregulates AMPK                                                                                                                                                       | [199]          |
| Vitamin D3         | Upregulates cathelicidin                                                                                                                                                                                               | [200,201]      |
| Vitamin C          | Antioxidant                                                                                                                                                                                                            | [202]          |
| Vitamin E          | Antioxidant                                                                                                                                                                                                            | [203]          |
| Lithium            | Lowers inositol and Ins(1,4,5)P" levels                                                                                                                                                                               | [204]          |
| Sodium valproate   | Lowers inositol and Ins(1,4,5)P" levels                                                                                                                                                                               | [196,204]      |
| Carbamazepine      | Lowers inositol and Ins(1,4,5)P" levels                                                                                                                                                                               | [196,204]      |
| Verapamil          | Lowers intracytosolic Ca^{2+} levels                                                                                                                                                                                   | [196]          |
| Clonidine and rilmenidine | Lower cAMP levels                                                                                                                                              | [196]          |
| Anti-psychotic drugs | Inhibit autophagy                                                                                                                                                                                                   | [205]          |
| Statins            | Statins preventing cholesterol-dependent pore-forming toxins from forming pores                                                                             |                |

**Pharmacological agents**

| 17-hydroxy-jolkolinolide B | Activates heme oxygenase-1 expression                                                                                                                      | [207]          |
| L-NAME                    | Decreases nitric oxide formation to induce autophagy                                                                                                     | [208]          |

**Nutritional compounds**

| Resveratrol               | Activates sirtuin 1 (histone deacetylase)                                                                                                                                 | [209–211]      |
| Epicatechins              | Inhibit LPS-induced HMGB1 upregulation by stimulating its autophagic degradation                                                                      | [212,213]      |
| Catalase                  | Antioxidant                                                                                                                                               | [214]          |
| Chloroquine               | Inhibits autophagosome-lysosome fusion                                                                                                                                 | [215,216]      |
| Vinblastine               | Inhibits microtubule formation                                                                                                                                 | [217]          |
| Nocodazole                | Inhibits microtubule formation and inhibits autophagosome-lysosome fusion                                                                             | [218,219]      |
| 3-methyladenine, Wortmannin | and LY294002 Inhibit phosphatidylinositol 3-3-kinase                                                                                                     | [220]          |

AMPK: AMP-activated protein kinase; cAMP cyclic AMP; Ins(1,4,5)P₃: inositol-1,4,5-triphosphate; L-NAME: N-l-arginine methyl ester; mTOR, mammalian target of rapamycin; mTORC1, mTOR complex 1; ULK1, Uncoordinated 51-like kinase 1; HMGB1, high mobility group B-1.

(1) Mammalian target of rapamycin complex 1 (mTORC1) inhibitors. Rapamycin (trade name Rapamune) and its analogs are macrolides produced by the bacterium Streptomyces hygroscopicus. Activators of AMPK, such as metformin (an antidiabetic drug) [221], and glucose starvation increase the AMP/ATP ratio, leading to an induction of AMP kinase activation, resulting in mTORC1 inhibition. Moreover, a diterpenoid from Euphorbia fischeriana that activates heme-oxygenase-1 (HO-1) expression [207] inhibits mTORC1 and enhances autophagy.

(2) Inhibitors of the phosphatidylinositol (PI) signaling pathway: lithium, valproic acid, carbamazepine. The PI signaling pathway is activated by cyclic AMP and EPAC (exchange protein activated by cAMP).
(3) Compounds linked in a potentially cyclic fashion via the pathway involving cyclic AMP, calcium and calpain: clonidine, rilmenidine and verapamil (agents used to treat hypertension and cardiac diseases), and anti-psychotic drugs.

(4) Other autophagy-modulating drugs: resveratrol, epicatechins, spermidine, vitamins, and inhibitors of nitric oxide formation, such as L-NAME.

4.1. mTOR Inhibitors

Mammalian target of rapamycin (mTOR), a serine-threonine kinase, is a central regulator of cellular metabolic homeostasis highly conserved throughout. The emerging role of mTOR signaling in the regulation of TLR-dependent innate responses and the activation of T cells and antigen-presenting cells has recently been reviewed [92], highlighting the importance of mTOR inhibition in the control of autophagy and intracellular bacterial clearance. As pointed out in previous publications [92], it is unclear whether bacterial pathogens can compete directly with infected host cells for nutrients, thereby contributing to the induction of metabolic stress pathways. It would be interesting to explore how drugs normally used to treat metabolic diseases influence the immune response. Metformin, for example, is used to modulate blood glucose levels and to inhibit mTORC1, which may induce inflammation. By contrast, it has been reported [222] that the treatment of Shigella-infected zebrafish with rapamycin may fail to promote host survival or bacterial clearance. This lack of efficacy of rapamycin may reflect effects on processes other than autophagy, because mTOR also affects many other cellular processes [223]. These findings indicate that caution is required concerning the therapeutic implications of autophagy upregulation.

The relationship between autophagy and the inflammatory processes induced by bacteria is well documented [38], and autophagy has been reported to play a prominent role in pulmonary diseases [224]. The activation of autophagy by antibiotic (isoniazid) treatment has been shown to decrease the proinflammatory responses induced by M. tuberculosis (MTb) in macrophages [199]. A number of therapies increasing autophagy activity are effective against MTb infection. The antiprotozoan drug nitazoxanide, and its active metabolite tizoxanide, strongly stimulate autophagy, inhibiting mTORC1 signaling and the intracellular proliferation of MTb [225].

The recent discovery of a functional impairment of autophagy in cystic fibrosis [226] provides a new basis for understanding susceptibility to severe infections. Treatments that restore autophagy may improve pathogen clearance and decrease lung inflammation in the airways of CF patients.

By contrast, Aguirre and coworkers [227] showed that autophagy blockade enhanced the lung response to endotoxemia and starvation, a potent autophagic stimulus. This, in turn, decreased lung injury, as reported by another group [228].

Moreover, adaptive responses to sepsis [229] are required to prevent organ failure and death. Cellular signaling responses that limit cell death and structural damage allow cells to withstand sepsis and prevent irreversible organ dysfunction. One such protective pathway for reducing hepatocellular injury is the upregulation of HO-1 signaling. HO-1 is upregulated in the liver in response to multiple stressors, including sepsis and LPS, and has been shown to limit cell death. Pharmacological inhibition of HO-1 activity with tin protoporphyrin or by HO-1 knockdown prevents the induction of autophagic signaling in these models and results in greater hepatocellular injury, apoptosis, and death [230]. Furthermore, the
inhibition of autophagy with 3-methyladenine or a small interfering RNA specific to VPS34, a class III phosphoinositide 3-kinase that acts as an upstream regulator of autophagy, results in hepatocyte apoptosis in vivo and in vitro. LPS induces the phosphorylation of p38 mitogen-activated protein kinase (p38 MAPK) at least partly by HO-1-dependent signaling. Moreover, the inhibition of p38 MAPK prevents CLP- or LPS-induced autophagy. Sepsis and LPS-induced autophagy protect against hepatocellular death, partly through HO-1 and p38 MAPK-dependent signaling. 17-hydroxy-jolkolinolide B, a diterpenoid from *E. fischeriana*, triggers HO-1 production in LPS-stimulated macrophages, potentially leading to the inhibition of inflammatory mediators [207]. Further investigations are required to determine how autophagic signaling prevents apoptosis and cell death.

4.2. Polyphenols

The engagement of TLRs or Fcγ receptors during phagocytosis induces the recruitment of the autophagy protein LC3 to phagosomes. TLR4 knockout mice have been reported to display lower levels of LT-induced cardiac dysfunction than control mice [231]. TLRs and Fcγ receptors are known to activate the NOX2 NADPH oxidase, which, through the release of ROS, play a major role in the killing of bacteria by phagocytes [61]. However, ROS overproduction can damage cells, as antioxidants can stimulate autophagy [232] and could be used as adjuvant treatments for infectious diseases [203,233]. Bacterial pathogens can manipulate autophagy by altering several processes, to ensure their survival and proliferation [234]. Autophagy may also act via an NADPH oxidase-dependent mechanism.

Anthrax lethal toxin (LT), a critical virulence factor secreted by *Bacillus anthracis*, alters murine cardiomyocyte contractile function via an NADPH oxidase-dependent pathway [235]. LT has also been shown to induce the accumulation of reactive oxygen species (ROS) and autophagy in murine cardiomyocytes. In a model of cardiac catalase overproduction, catalase, an antioxidant enzyme, was found to attenuate LT-induced cardiac contractile and intracellular Ca2+ abnormalities. Catalase decreased the LT-induced increase in LC3-II levels, indicating a possible role for ROS in LT-induced autophagosome formation [214]. Moreover, Toll-like receptor 4 (TLR4) knockout was found to prevent LT-induced cardiac abnormalities, possibly through a mechanism associated with autophagy [231].

Kandadi’s group proposed an experimental murine model of cardiac-specific catalase overexpression protecting against *B. anthracis* LT, to improve antioxidant pathway targeting [214]. Another group of antioxidants, polyphenols from green tea, such as epigallocatechin-3-gallate (EGCG) was also tested. This antioxidant prevented death due to the effects of LT in rats [236]. This polyphenol is a well known anti-infectious compound [233,237]. However, some studies have shown that high concentrations of EGCG (100 µM) inhibit autophagy, leading to apoptosis in macrophage cell lines [238]. By contrast, low concentrations of EGCG (10 µM) induce autophagy, enhancing the degradation of LPS-induced aggregates of high mobility group B-1 (HMGB1), leading to anti-inflammatory effects [212]. As reported by Kim *et al.* [239], EGCG stimulates autophagy in endothelial cells via a Ca2+/CaMKKβ/AMPK-dependent mechanism (CaMKKβ = calmodulin-dependent protein kinase kinase β). Another polyphenol, resveratrol, induces autophagy in various models [232,240] and reduces endotoxin-induced cardiotoxicity [241]. In addition having antioxidant activity, resveratrol induces autophagy by activating a protein acetylase called sirtuin 1 [242–244]. It stimulates the deacetylation of cytoplasmic proteins by a sirtuin 1-dependent mechanism [243,245]. Pietrocola *et al.* [246] showed that
a strong correlation and cause-effect relationship between cytoplasmic deacetylation reactions and the induction of autophagy could explain the effect of resveratrol. Only a few in vivo studies have been published and further studies of the utility of antioxidants for regulating the autophagic pathway are required. Moreover, a recent review [247] of the use of antioxidant therapy in cystic fibrosis reported poor evidence regarding clinical outcome. However, the mechanisms involved need to be determined and new pharmacological tools developed for testing in in vivo experimental models.

4.3. Vitamins

Another strategy is based on the stimulation of innate defense. Several authors [200,201] have reported that vitamin D3 induces autophagy in human monocytes/macrophages via cathelicidin, thus demonstrating a relationship relationship between vitD3-induced innate defense and autophagy activation. However, as highlighted in one study [248], limited data are available concerning the potential utility of pharmaceutical agents that induce autophagy as therapeutic agents for human infectious diseases. Other vitamins, such as vitamin C [202] and vitamin E [203], may have beneficial effects against sepsis, via the activation of autophagy and an increase in the elimination of damaged cell components.

Figure 3 shows a simplified overview of the regulation of bacterial autophagy (xenophagy) and potential drug targets likely to enhance autophagy. For example, numerous inhibitors of the cAMP/PKA pathway could be tested, to analyze their effect on the autophagic response and bacterial clearance. One recent study showed that a PKA inhibitor, H-89, could stimulate autophagy [249], but this effect appeared to be independent of PKA inhibition.

4.4. Adenosine Receptor Agonists

However, these pathways, involving numerous molecules, including mTORC1, can affect many processes other than autophagy. For example, they can inhibit AKT, a serine-threonine kinase involved in tumorigenesis and cell motility, thereby increasing susceptibility to cell death [250]. Data from Popov and coworkers [183] have shown that adenosine type-3 receptor agonists, such as N6-(3-iodobenzyl) adenosine-5'-N-methyluronamide can improve the outcome of antibiotic treatment in a murine model of anthrax. The authors put forward several possible explanations for their results, including AKT stimulation and cAMP downregulation. These agonists have been shown to protect against endotoxemia, and to decrease mortality in sepsis [251–253]. They have not been reported to affect autophagy, but the A1 adenosine receptor agonist (2 chloro-N6-cyclopentyladenosine) has been shown to stimulate the autophagic pathway [254]. As reported by Factor and coworkers [255], the A1R and A3R receptors inhibit adenylyl cyclase or lead to signaling through inositol-3-phosphate and phospholipase C in most cell systems. By contrast, the engagement of type 2 receptors activates adenylyl cyclase via Gsα and increases cAMP levels (for a review of the role of adenosine receptors in immune diseases, see [256]).
Figure 3. A simplified overview (a modified schema from [2]) of some molecular events (and potential drug targets) involved in bacterial autophagy. For example, the increase in intracellular calcium concentration leads to the activation of calpains, which inhibit autophagy. Inhibitors of calcium or calpain could therefore interfere with the autophagic pathway. Inflammatory mediators, such as cytokines, trigger PI3K activation, leading to a decrease in autophagosomes through effects on mTORC1. PI3K inhibitors or rapamycin treatment to inhibit mTORC1 enhances autophagy. Glucose starvation, which can be induced by stress, activates AMPK, leading to the inhibition of mTORC1 and the stimulation of autophagy. Membrane damage by pore-forming toxins induces starvation responses [120]. Loss of cellular potassium from perforated cells leads to the failure of nutrient transport and transient drop of ATP, thus activating cellular nutrient and energy sensors GCN2 and AMPK, subsequent phosphorylation of EIF2α and deactivation of mTORC1. Bacterial toxins, such as those with adenylate cyclase activity (ACs), enhance cAMP production, leading to an activation of the inositol pathway. InsP3 inhibits autophagy, and drugs such as lithium (Li) and valproic acid block the inositol cycle, restoring autophagy. The overproduction of cAMP activates the PKA pathway, potentially impairing the localization of Atg1 and Atg13 to the phagophore assembly site, resulting in defective autophagy. Motifs from bacteria or endotoxins are recognized by TLRs, which activate numerous pathways. For example, those triggering the HO-1 pathway can activate autophagy by activating mitochondrial ROS and p38 MAPK. However, endotoxins can induce oxygen stress and ROS overproduction, via the TLRs, either enhancing or inhibiting autophagy. Antioxidants, such as catalase and resveratrol, strongly enhance or restore the autophagic pathway.
4.5. Antipsychotic Drugs

As reported by Shaw’s group [205], small-molecule inducers of basal autophagy have been characterized according to their effects on IL-1β production, autophagic engulfment and the killing of intracellular bacteria. These inducers include antipsychotic drugs, bromperidol, metergoline phenothiazine thioridazine, chlorpromazine and clemastine (an antihistamine). Astemizole, a second-generation selective histamine H1-receptor antagonist that acts as a potent inducer of autophagy, significantly improves survival outcomes in a mouse model of prion disease [257]. The mechanism by which astemizole modulates autophagy has not been characterized, but this drug has been reported to have antifungal [258] and antimalaria [259] effects. Another small molecule, pimozide, an antipsychotic drug, has been reported to inhibit \( L. \) monocytogenes infection [260]. The inhibitory effect of pimozide on internalization was not specific to \( L. \) monocytogenes, as the phagocytosis of other bacterial species (\( Bacillus \) subtilis, \( Salmonella \) enterica, serovar Typhimurium and \( E. \) coli K12) was significantly inhibited in the presence of pimozide. Moreover, the antipsychotic drug thioridazine and the calcium channel blocker bepridil inhibit vacuolar escape and the intracellular replication of \( L. \) monocytogenes in a dose-dependent manner during the infection of murine macrophages [261]. Nevertheless, the surprising links between an antipsychotic drug, an antibacterial effect and the autophagic pathway require further exploration.

4.6. Statins

Cholesterol is a key component of autophagosome membranes, and drugs that modulate cholesterol turnover may play a major role in regulating autophagosome formation. Well known drugs, such as statins [193], act as competitive inhibitors of HMG-CoA reductase, a rate-limiting enzyme of the cholesterol biosynthesis pathway catalyzing the conversion of HMG-CoA reductase into mevalonate [262]. It has been suggested that statins have pleiotropic effects, including broad-range immunomodulatory and anti-inflammatory properties [263,264]. Statins have been shown to decrease mortality in patients with bacteremia [265] and to improve multiple organ dysfunction syndrome [266]. Simvastatin has been shown to increase protection against \( Listeria \) monocytogenes infection in mice, by counteracting \( Listeria \)-induced phagosomal escape [206]. Statins have been studied in diverse models of infection, including an experimental \( Plasmodium \) berghei cerebral malaria model in rodents. Statin treatment was found to improve the efficacy of antimalarial products, such as mefloquine, and to decrease neuroinflammation [267,268]. Further investigations are required to determine the role of autophagy in this model.

The hypothesis that statin treatment can alter the effects of pore-forming toxins in host cells requires further investigation (the cholesterol-dependent cytolysin pore complex is reviewed in [269]), as these toxins contribute to the virulence of numerous bacterial pathogens [270].

According to Rubinsztein [2], caution is required when considering the use of autophagy-inducing agents for the treatment of patients with infections that may be alleviated by the upregulation of autophagy (such as tuberculosis). This is particularly true if these patients are coinfected with other pathogens that can exploit the autophagy pathway. Another potential concern is that excessively high levels of autophagy may exacerbate certain infectious diseases. For example, the inhibition of autophagy
has been shown to improve acute lung injury caused by avian influenza A H5N1 infection [271]. The autophagic response in septic lungs is a protective response. However, autophagy following excessively high levels of autophagosome accumulation may be maladaptive in the late stage of sepsis, ultimately leading to acute lung injury [272].

Following on from studies of the autophagic pathway, a new generation of vaccines [31] could be developed for the future. These vaccines could include attenuated vaccines already in use and produced from bacterial strains specifically constructed so as not to replicate within the host cell or spread from cell to cell. Bacteria could be engineered to prevent their entry into the cytosol, through the introduction of genes mediating vacuolar lysis. Moreover, the delivery of antigens into this vacuolar compartment should enhance the presentation of class I major histocompatibility complex molecules and elicit cytotoxic T-cell responses.

As reported by Schein et al. [273], a new strategy for counteracting bacterial adenylate cyclase activity involves a combination of structural and computational approaches. This approach involves the selection of small organic molecules binding to residues within the substrate binding pocket of an adenylate cyclase, such as B. anthracis EF, from large, web-based compound libraries, on the basis of their docking scores. A family of fluorenone-based inhibitors has been identified, the members of which inhibit the release of cAMP from cells treated with EF. The lead inhibitor was also shown to prevent the diarrhea caused by enterotoxigenic E. coli (ETEC) in a murine model, possibly by serving as a quorum sensor. The ability of these inhibitors to inhibit anthrax could be tested in animal models, along with their ability to inhibit toxins similar to EF, such as toxins from B. pertussis or V. cholerae. Finally, cells or their products could be used to obtain an antibacterial effect. It has recently been reported [274] that mesenchymal stem cells (MSCs) can modulate autophagy in a parkinsonian model, and MSCs have also been reported to increase the antibacterial activity of granulocytes [275]. The mechanisms involved in the effects of MSCs on antibacterial activity, based on cell contact or soluble factors, need to be deciphered, and this will require determination of the precise role of autophagy in these processes.

5. Conclusions

Autophagy represents a host defense pathway against pathogens and bacterial products, such as LPS, PFTs and bacterial adenylate cyclases. Autophagic pathways are altered by the bacterial toxins involved in pathogenicity, but other host cell signaling pathways also enhance bacterial survival within the cell. Further studies are required to decipher the mechanisms of pathogen recognition and host cell responses, for the development of new pharmacological strategies to use in conjunction with antibiotics against bacterial pathogens.

Acknowledgments

We thank Jean-Nicolas Tournier and Bradley Stiles for providing helpful advice during the writing of the manuscript and for their critical reading.
Conflicts of Interest

The author has no conflict of interest to declare.

References

1. Shahnazari, S.; Brumell, J. Mechanisms and consequences of bacterial targeting by the autophagy pathway. *Curr. Opin. Microbiol.* 2011, 14, 68–75.
2. Rubinsztein, D.; Codogno, P.; Levine, B. Autophagy modulation as a potential therapeutic target for diverse diseases. *Nat. Rev. Drug Discov.* 2012, 11, 709–730.
3. Yang, Z.; Klionsky, D. Mammalian autophagy: Core molecular machinery and signaling regulation. *Curr. Opin. Cell Biol.* 2010, 22, 124–131.
4. Fimia, G.; Piacentini, M. Regulation of autophagy in mammals and its interplay with apoptosis. *Cell Mol. Life Sci.* 2010, 67, 1581–1588.
5. Kroemer, G.; Marino, G.; Levine, B. Autophagy and the integrated stress response. *Mol. Cell* 2010, 40, 280–293.
6. Meijer, A.; Codogno, P. Autophagy: Regulation and role in disease. *Crit. Rev. Clin. Lab. Sci.* 2009, 46, 210–240.
7. Levine, B.; Yuan, J. Autophagy in cell death: An innocent convict? *J. Clin. Invest.* 2005, 115, 2679–2688.
8. Levine, B.; Sinha, S.; Kroemer, G. Bcl-2 family members: Dual regulators of apoptosis and autophagy. *Autophagy* 2008, 4, 600–606.
9. Maiuri, M.; Zalckvar, E.; Kimchi, A.; Kroemer, G. Self-eating and self-killing: Crosstalk between autophagy and apoptosis. *Nat. Rev. Mol. Cell Biol.* 2007, 8, 741–752.
10. Klionsky, D.; Abdalla, F.; Abeliovich, H.; Abraham, R.; Acevedo-Arozena, A.; Adeli, K.; Agholme, L.; Agnello, M.; Agostinis, P.; Aguirre-Ghiso, J.; et al. Guidelines for the use and interpretation of assays for monitoring autophagy. *Autophagy* 2012, 8, 445–544.
11. Sahu, R.; Kaushik, S.; Clement, C.C.; Cannizzo, E.S.; Scharf, B.; Follenzi, A.; Potolicchio, I.; Nieves, E.; Cuervo, A.M.; Santambrogio, L. Microautophagy of cytosolic proteins by late endosomes. *Dev. Cell* 2011, 20, 131–139.
12. Santambrogio, L.; Cuervo, A.M. Chasing the elusive mammalian microautophagy. *Autophagy* 2011, 7, 652–654.
13. Klionsky, D.; Baehrecke, E.; Brumell, J.; Chu, C.; Codogno, P.; Cuervo, A.; Debnath, J.; Deretic, V.; Elazar, Z.; Eskelinen, E.; et al. A comprehensive glossary of autophagy-related molecules and processes (2nd edition). *Autophagy* 2011, 7, 1273–1294.
14. Lemasters, J.J. Selective mitochondrial autophagy, or mitophagy, as a targeted defense against oxidative stress, mitochondrial dysfunction, and aging. *Rejuvenation Res.* 2005, 8, 3–5.
15. Cuervo, A.M. Chaperone-mediated autophagy: Selectivity pays off. *Trends Endocrinol. Metab.* 2010, 21, 142–150.
16. Dice, J.F. Chaperone-mediated autophagy. *Autophagy* 2007, 3, 295–299.
17. Kaushik, S.; Bandyopadhyay, U.; Sridhar, S.; Kiffin, R.; Martinez-Vicente, M.; Kon, M.; Orenstein, S.J.; Wong, E.; Cuervo, A.M. Chaperone-mediated autophagy at a glance. *J. Cell Sci.* 2011, 124, 495–499.

18. Cuervo, A.M.; Dice, J.F. A receptor for the selective uptake and degradation of proteins by lysosomes. *Science* 1996, 273, 501–503.

19. Agarraberes, F.A.; Terlecky, S.R.; Dice, J.F. An intralysosomal hsp70 is required for a selective pathway of lysosomal protein degradation. *J. Cell Biol.* 1997, 137, 825–834.

20. Singh, R.; Kaushik, S.; Wang, Y.; Xiang, Y.; Novak, I.; Komatsu, M.; Tanaka, K.; Cuervo, A.M.; Czaja, M.J. Autophagy regulates lipid metabolism. *Nature* 2009, 458, 1131–1135.

21. Levine, B. Eating oneself and uninvited guests: Autophagy-related pathways in cellular defense. *Cell* 2005, 120, 159–162.

22. Devenish, R.J.; Lai, S.C. Autophagy and burkholderia. *Immunol. Cell Biol.* 2015, 93, 18–24.

23. Lamb, C.A.; Yoshimori, T.; Tooze, S.A. The autophagosome: Origins unknown, biogenesis complex. *Nat. Rev. Mol. Cell Biol.* 2013, 14, 759–774.

24. Codogno, P.; Mehrpour, M.; Proikas-Cezanne, T. Canonical and non-canonical autophagy: Variations on a common theme of self-eating? *Nat. Rev. Mol. Cell Biol.* 2012, 13, 7–12.

25. Sanjuan, M.; Milasta, S.; Green, D. Toll-like receptor signaling in the lysosomal pathways. *Immunol. Rev.* 2009, 227, 203–220.

26. Mostowy, S. Autophagy and bacterial clearance: A not so clear picture. *Cell Microbiol.* 2013, 15, 395–402.

27. Haas, A. The phagosome: Compartment with a license to kill. *Traffic* 2007, 8, 311–330.

28. Sansonetti, P.J. Rupture, invasion and inflammatory destruction of the intestinal barrier by Shigella, making sense of prokaryote-eukaryote cross-talks. *FEMS Microbiol. Rev.* 2001, 25, 3–14.

29. Cossart, P.; Sansonetti, P.J. Bacterial invasion: The paradigms of enteroinvasive pathogens. *Science* 2004, 304, 242–248.

30. Schroeder, G.N.; Hilbi, H. Molecular pathogenesis of Shigella spp.: Controlling host cell signaling, invasion, and death by type III secretion. *Clin. Microbiol. Rev.* 2008, 21, 134–156.

31. Ray, K.; Marteyn, B.; Sansonetti, P.; Tang, C. Life on the inside: The intracellular lifestyle of cytolic bacteria. *Nat. Rev. Microbiol.* 2009, 7, 333–340.

32. Morris, M.C.; Gilliam, E.A.; Li, L. Innate immune programing by endotoxin and its pathological consequences. *Front. Immunol.* 2014, 5, 680.

33. Rhee, S.H. Lipopolysaccharide: Basic biochemistry, intracellular signaling, and physiological impacts in the gut. *Intest. Res.* 2014, 12, 90–95.

34. Cui, J.; Chen, Y.; Wang, H.Y.; Wang, R.F. Mechanisms and pathways of innate immune activation and regulation in health and cancer. *Hum. Vaccin Immunother.* 2014, 10, 3270–3285.

35. Kim, M.G.; Yang, J.H.; Kim, K.M.; Jang, C.H.; Jung, J.Y.; Cho, I.J.; Shin, S.M.; Ki, S.H. Regulation of Toll-like receptor-mediated Sestrin2 induction by AP-1, Nrf2, and the ubiquitin-proteasome system in macrophages. *Toxicol. Sci.* 2015, 144, 425–435.

36. Tweten, R. Cholesterol-dependent cytolysins, a family of versatile pore-forming toxins. *Infect. Immun.* 2005, 73, 6199–6209.

37. Cemma, M.; Brumell, J. Interactions of pathogenic bacteria with autophagy systems. *Curr. Biol.* 2012, 22, R540–R545.
38. Deretic, V.; Saitoh, T.; Akira, S. Autophagy in infection, inflammation and immunity. Nat. Rev. Immunol. 2013, 13, 722–737.
39. Deretic, V.; Levine, B. Autophagy, immunity, and microbial adaptations. Cell. Host Microbe 2009, 5, 527–549.
40. Amer, A.; Byrne, B.; Swanson, M. Macrophages rapidly transfer pathogens from lipid raft vacuoles to autophagosomes. Autophagy 2005, 1, 53–58.
41. Klionsky, D.; Cregg, J.; Dunn, W.J.; Emr, S.; Sakai, Y.; Sandoval, I.; Sibirny, A.; Subramani, S.; Thumm, M.; Veenhuis, M.; et al. A unified nomenclature for yeast autophagy-related genes. Dev. Cell 2003, 5, 539–545.
42. Kabeya, Y.; Mizushima, N.; Ueno, T.; Yamamoto, A.; Kirisako, T.; Noda, T.; Kominami, E.; Ohsumi, Y.; Yoshimori, T. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J. 2000, 19, 5720–5728.
43. Weidberg, H.; Shvets, E.; Shpilka, T.; Shimron, F.; Shinder, V.; Elazar, Z. LC3 and GATE-16/GABARAP subfamilies are both essential yet act differently in autophagosome biogenesis. EMBO J. 2010, 29, 1792–1802.
44. Cherrera, S.J., 3rd; Kulich, S.M.; Uechi, G.; Balasubramani, M.; Mountzouris, J.; Day, B.W.; Chu, C.T. Regulation of the autophagy protein LC3 by phosphorylation. J. Cell Biol. 2010, 190, 533–539.
45. Hanada, T.; Noda, N.; Satomi, Y.; Ichimura, Y.; Fujioka, Y.; Takao, T.; Inagaki, F.; Ohsumi, Y. The Atg12-Atg5 conjugate has a novel E3-like activity for protein lipidation in autophagy. J. Biol. Chem. 2007, 282, 37298–37302.
46. Nishida, Y.; Arakawa, S.; Fujitani, K.; Yamaguchi, H.; Mizuta, T.; Kanaseki, T.; Komatsu, M.; Otsu, K.; Tsujimoto, Y.; Shimizu, S. Discovery of Atg5/Atg7-independent alternative macroautophagy. Nature 2009, 461, 654–658.
47. Shimizu, S.; Arakawa, S.; Nishida, Y. Autophagy takes an alternative pathway. Autophagy 2010, 6, 290–291.
48. Collins, C.A.; de Maziere, A.; van Dijk, S.; Carlsson, F.; Klumperman, J.; Brown, E.J. Atg5-independent sequestration of ubiquitinated mycobacteria. PLoS Pathog. 2009, 5, e1000430.
49. Mehta, P.; Henault, J.; Kolbeck, R.; Sanjuan, M. Noncanonical autophagy: One small step for LC3, one giant leap for immunity. Curr. Opin. Immunol. 2014, 26, 69–75.
50. Randow, F.; Munz, C. Autophagy in the regulation of pathogen replication and adaptive immunity. Trends Immunol. 2012, 33, 475–487.
51. Celli, J. LRSAM1, an E3 Ubiquitin ligase with a sense for bacteria. Cell Host Microbe 2012, 12, 735–736.
52. Quezada, C.M.; Hicks, S.W.; Galan, J.E.; Stebbins, C.E. A family of Salmonella virulence factors functions as a distinct class of autoregulated E3 ubiquitin ligases. Proc. Natl. Acad. Sci. USA 2009, 106, 4864–4869.
53. Huett, A.; Heath, R.J.; Begun, J.; Sassi, S.O.; Baxt, L.A.; Vyas, J.M.; Goldberg, M.B.; Xavier, R.J. The LRR and RING domain protein LRSAM1 is an E3 ligase crucial for ubiquitin-dependent autophagy of intracellular Salmonella Typhimurium. Cell Host Microbe 2012, 12, 778–790.
54. Lin, X.W.; Xu, W.C.; Luo, J.G.; Guo, X.J.; Sun, T.; Zhao, X.L.; Fu, Z.J. WW domain containing E3 ubiquitin protein ligase 1 (WWP1) negatively regulates TLR4-mediated TNF-alpha and IL-6 production by proteasomal degradation of TNF receptor associated factor 6 (TRAF6). *PLoS ONE* **2013**, *8*, e67633.

55. Zheng, Y.T.; Shahnazari, S.; Brech, A.; Lamark, T.; Johansen, T.; Brumell, J.H. The adaptor protein p62/SQSTM1 targets invading bacteria to the autophagy pathway. *J. Immunol.* **2009**, *183*, 5909–5916.

56. Birmingham, C.L.; Smith, A.C.; Bakowski, M.A.; Yoshimori, T.; Brumell, J.H. Autophagy controls Salmonella infection in response to damage to the Salmonella-containing vacuole. *J. Biol. Chem.* **2006**, *281*, 11374–11383.

57. Cemma, M.; Kim, P.K.; Brumell, J.H. The ubiquitin-binding adaptor proteins p62/SQSTM1 and NDP52 are recruited independently to bacteria-associated microdomains to target Salmonella to the autophagy pathway. *Autophagy* **2011**, *7*, 341–345.

58. Thurston, T.L.; Ryzhakov, G.; Bloor, S.; von Muhlinen, N.; Randow, F. The TBK1 adaptor and autophagy receptor NDP52 restricts the proliferation of ubiquitin-coated bacteria. *Nat. Immunol.* **2009**, *10*, 1215–1221.

59. Mostowy, S.; Sancho-Shimizu, V.; Hamon, M.; Simeone, R.; Brosch, R.; Johansen, T.; Cossart, P. p62 and NDP52 proteins target intracytosolic Shigella and Listeria to different autophagy pathways. *J. Biol. Chem.* **2011**, *286*, 26987–26995.

60. Sanjuan, M.; Dillon, C.; Tait, S.; Moshiach, S.; Dorsey, F.; Connell, S.; Komatsu, M.; Tanaka, K.; Cleveland, J.; Withoff, S.; et al. Toll-Like receptor signalling in macrophages links the autophagy pathway to phagocytosis. *Nature* **2007**, *450*, 1253–1257.

61. Huang, J.; Canadien, V.; Lam, G.; Steinberg, B.; Dinauer, M.; Magalhaes, M.; Glogauer, M.; Grinstein, S.; Brumell, J. Activation of antibacterial autophagy by NADPH oxidases. *Proc. Natl. Acad. Sci. USA* **2009**, *106*, 6226–6231.

62. Gong, L.; Cullinane, M.; Treerat, P.; Ramm, G.; Prescott, M.; Adler, B.; Boyce, J.; Devenish, R. The Burkholderia pseudomallei type III secretion system and BopA are required for evasion of LC3-associated phagocytosis. *PLoS ONE* **2011**, *6*, e17852.

63. Lam, G.; Cemma, M.; Muise, A.; Higgins, D.; Brumell, J. Host and bacterial factors that regulate LC3 recruitment to Listeria monocytogenes during the early stages of macrophage infection. *Autophagy* **2013**, *9*, 985–995.

64. Martinez, J.; Almendinger, J.; Oberst, A.; Ness, R.; Dillon, C.P.; Fitzgerald, P.; Hengartner, M.O.; Green, D.R. Microtubule-associated protein 1 light chain 3 alpha (LC3)-associated phagocytosis is required for the efficient clearance of dead cells. *Proc. Natl. Acad. Sci. USA* **2011**, *108*, 17396–17401.

65. Lai, S.C.; Devenish, R.J. LC3-Associated Phagocytosis (LAP): Connections with Host Autophagy. *Cells* **2012**, *1*, 396–408.

66. Lippai, M.; Low, P. The role of the selective adaptor p62 and ubiquitin-like proteins in autophagy. *Biomed. Res. Int.* **2014**, *2014*, 832704.

67. Pankiv, S.; Clausen, T.H.; Lamark, T.; Brech, A.; Bruun, J.A.; Outzen, H.; Overvatn, A.; Bjorkoy, G.; Johansen, T. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinitated protein aggregates by autophagy. *J. Biol. Chem.* **2007**, *282*, 24131–24145.
68. Ciani, B.; Layfield, R.; Cavey, J.R.; Sheppard, P.W.; Searle, M.S. Structure of the ubiquitin-associated domain of p62 (SQSTM1) and implications for mutations that cause Paget’s disease of bone. *J. Biol. Chem.* 2003, 278, 37409–37412.

69. Komatsu, M.; Waguri, S.; Koike, M.; Sou, Y.S.; Ueno, T.; Hara, T.; Mizushima, N.; Iwata, J.; Ezaki, J.; Murata, S.; et al. Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice. *Cell* 2007, 131, 1149–1163.

70. Nezis, I.P.; Simonsen, A.; Sagona, A.P.; Finley, K.; Gaumer, S.; Contamine, D.; Rusten, T.E.; Stenmark, H.; Brech, A. Ref(2)P, the Drosophila melanogaster homologue of mammalian p62, is required for the formation of protein aggregates in adult brain. *J. Cell Biol.* 2008, 180, 1065–1071.

71. Boyle, K.B.; Randow, F. The role of “eat-me” signals and autophagy cargo receptors in innate immunity. *Curr. Opin. Microbiol.* 2013, 16, 339–348.

72. Duran, A.; Amanchy, R.; Linares, J.F.; Joshi, J.; Abu-Baker, S.; Porollo, A.; Hansen, M.; Moscat, J.; Diaz-Meco, M.T. p62 is a key regulator of nutrient sensing in the mTORC1 pathway. *Mol. Cell* 2011, 44, 134–146.

73. Ishimura, R.; Tanaka, K.; Komatsu, M. Dissection of the role of p62/Sqstm1 in activation of Nrf2 during xenophagy. *FEBS Lett.* 2014, 588, 822–828.

74. Sorbara, M.T.; Girardin, S.E. Emerging themes in bacterial autophagy. *Curr. Opin. Microbiol.* 2015, 23C, 163–170.

75. Philpott, D.J.; Girardin, S.E. Nod-like receptors: Sentinels at host membranes. *Curr. Opin. Immunol.* 2010, 22, 428–434.

76. Travassos, L.H.; Carneiro, L.A.; Ramjeeet, M.; Hussey, S.; Kim, Y.G.; Magalhaes, J.G.; Yuan, L.; Soares, F.; Chea, E.; Le Bourhis, L.; et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. *Nat. Immunol.* 2010, 11, 55–62.

77. Thurston, T.L.; Wandel, M.P.; von Muhlinen, N.; Foegle, A.; Randow, F. Galectin 8 targets damaged vesicles for autophagy to defend cells against bacterial invasion. *Nature* 2012, 482, 414–418.

78. Shahnazari, S.; Yen, W.L.; Birmingham, C.L.; Shiu, J.; Namolovan, A.; Zheng, Y.T.; Nakayama, K.; Klionsky, D.J.; Brumell, J.H. A diacylglycerol-dependent signaling pathway contributes to regulation of antibacterial autophagy. *Cell Host Microbe* 2010, 8, 137–146.

79. Shahnazari, S.; Namolovan, A.; Klionsky, D.J.; Brumell, J.H. A role for diacylglycerol in antibacterial autophagy. *Autophagy* 2011, 7, 331–333.

80. Moreau, K.; Lacas-Gervais, S.; Fujita, N.; Sebbane, F.; Yoshimori, T.; Simonet, M.; Lafont, F. Autophagosomes can support Yersinia pseudotuberculosis replication in macrophages. *Cell Microbiol.* 2010, 12, 1108–1123.

81. Cooney, R.; Baker, J.; Brain, O.; Danis, B.; Pichulik, T.; Allan, P.; Ferguson, D.; Campbell, B.; Jewell, D.; Simmons, A. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. *Nat. Med.* 2010, 16, 90–97.

82. Shi, C.; Shenderov, K.; Huang, N.; Kabat, J.; Abu-Asab, M.; Fitzgerald, K.; Sher, A.; Kehrl, J. Activation of autophagy by inflammatory signals limits IL-1beta production by targeting ubiquitinated inflammasomes for destruction. *Nat. Immunol.* 2012, 13, 255–263.

83. Knodler, L.; Celli, J. Eating the strangers within: Host control of intracellular bacteria via xenophagy. *Cell Microbiol.* 2011, 13, 1319–1327.
84. Saitoh, S. Chaperones and transport proteins regulate TLR4 trafficking and activation. *Immunobiology* **2009**, *214*, 594–600.

85. Saitoh, T.; Fujita, N.; Jang, M.; Uematsu, S.; Yang, B.; Satoh, T.; Omori, H.; Noda, T.; Yamamoto, N.; Komatsu, M.; *et al.* Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. *Nature* **2008**, *456*, 264–268.

86. Nakahira, K.; Haspel, J.; Rathinam, V.; Lee, S.; Dolinay, T.; Lam, H.; Englert, J.; Rabinovitch, M.; Cernadas, M.; Kim, H.; *et al.* Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. *Nat. Immunol.* **2011**, *12*, 222–230.

87. Delgado, M.; Deretic, V. Toll-like receptors in control of immunological autophagy. *Cell Death Differ.* **2009**, *16*, 976–983.

88. Shi, C.; Kehrl, J. MyD88 and Trif target Beclin 1 to trigger autophagy in macrophages. *J. Biol. Chem.* **2008**, *283*, 33175–33182.

89. Wei, Y.; Pattingre, S.; Sinha, S.; Bassik, M.; Levine, B. JNK1-mediated phosphorylation of Bcl-2 regulates starvation-induced autophagy. *Mol. Cell* **2008**, *30*, 678–688.

90. Scherz-Shouval, R.; Elazar, Z. Regulation of autophagy by ROS: Physiology and pathology. *Trends Biochem. Sci.* **2011**, *36*, 30–38.

92. Abdel-Nour, M.; Tsalikis, J.; Kleinman, D.; Girardin, S. The emerging role of mTOR signalling in antibacterial immunity. *Immunol. Cell. Biol.* **2014**, *92*, 346–353.

93. Araki, K.; Ellebedy, A.; Ahmed, R. TOR in the immune system. *Curr. Opin. Cell Biol.* **2011**, *23*, 707–715.

94. Tsalikis, J.; Croitoru, D.; Philpott, D.; Girardin, S. Nutrient sensing and metabolic stress pathways in innate immunity. *Cell Microbiol.* **2013**, *15*, 1632–1641.

95. Salh, B.; Wagey, R.; Marotta, A.; Tao, J.; Pelech, S. Activation of phosphatidylinositol 3-kinase, protein kinase B, and p70 S6 kinases in lipopolysaccharide-stimulated Raw 264.7 cells: Differential effects of rapamycin, Ly294002, and wortmannin on nitric oxide production. *J. Immunol.* **1998**, *161*, 6947–6954.

96. Potter, M.; Shah, S.; Elbirt, K.; Callery, M. Endotoxin (LPS) stimulates 4E-BP1/PHAS-I phosphorylation in macrophages. *J. Surg. Res.* **2001**, *97*, 54–59.

97. Wullschleger, S.; Loewith, R.; Hall, M. TOR signaling in growth and metabolism. *Cell* **2006**, *124*, 471–484.

98. Lang, C.; Frost, R. Endotoxin disrupts the leucine-signaling pathway involving phosphorylation of mTOR, 4E-BP1, and S6K1 in skeletal muscle. *J. Cell Physiol.* **2005**, *203*, 144–155.

99. Dos Santos, S.; Delattre, A.; de Longueville, F.; Bult, H.; Raes, M. Gene expression profiling of LPS-stimulated murine macrophages and role of the NF-kappaB and PI3K/mTOR signaling pathways. *Ann. N. Y. Acad. Sci.* **2007**, *1096*, 70–77.

100. Troutman, T.; Bazan, J.; Pasare, C. Toll-like receptors, signaling adapters and regulation of the pro-inflammatory response by PI3K. *Cell Cycle* **2012**, *11*, 3559–3567.
101. Lee, D.; Kuo, H.; Chen, C.; Hsu, J.; Chou, C.; Wei, Y.; Sun, H.; Li, L.; Ping, B.; Huang, W.; et al. IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. *Cell* **2007**, *130*, 440–455.

102. Manning, B.; Tee, A.; Logsdon, M.; Blenis, J.; Cantley, L. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. *Mol. Cell* **2002**, *10*, 151–162.

103. Weichhart, T.; Costantino, G.; Poglitsch, M.; Rosner, M.; Zeyda, M.; Stuhlmeier, K.; Kolbe, T.; Stulnig, T.; Horl, W.; Hengstschlager, M.; *et al.* The TSC-mTOR signaling pathway regulates the innate inflammatory response. *Immunity* **2008**, *29*, 565–577.

104. Girardin, S.E.; Boneca, I.G.; Carneiro, L.A.; Antignac, A.; Jehanno, M.; Viala, J.; Tedin, K.; Tah, M.K.; Labigne, A.; Zahringer, U.; *et al.* Nod1 detects a unique muramopeptide from gram-negative bacterial peptidoglycan. *Science* **2003**, *300*, 1584–1587.

105. Kufer, T.A.; Banks, D.J.; Philpott, D.J. Innate immune sensing of microbes by Nod proteins. *Ann. N. Y. Acad. Sci.* **2006**, *1072*, 19–27.

106. Franchi, L.; Warner, N.; Viani, K.; Nunez, G. Function of Nod-like receptors in microbial recognition and host defense. *Immunol. Rev.* **2009**, *227*, 106–128.

107. Gonzalez, M.R.; Bischofberger, M.; Perrot, L.; van der Goot, F.G.; Freche, B. Bacterial pore-forming toxins: The (w)hole story? *Cell Mol. Life Sci.* **2008**, *65*, 493–507.

108. Lakey, J.H.; Slatin, S.L. Pore-forming colicins and their relatives. *Curr. Top. Microbiol. Immunol.* **2001**, *257*, 131–161.

109. Pezard, C.; Berche, P.; Mock, M. Contribution of individual toxin components to virulence of *Bacillus anthracis*. *Infec. Immun.* **1991**, *59*, 3472–3477.

110. Parker, M.W.; Feil, S.C. Pore-forming protein toxins: From structure to function. *Prog. Biophys. Mol. Biol.* **2005**, *88*, 91–142.

111. Pellizzari, R.; Guidi-Rontani, C.; Vitale, G.; Mock, M.; Montecucco, C. Lethal factor of *Bacillus anthracis* cleaves the N-terminus of MAPKKs: Analysis of the intracellular consequences in macrophages. *Int. J. Med. Microbiol.* **2000**, *290*, 421–427.

112. Agarwal, N.; Bishai, W. cAMP signaling in *Mycobacterium tuberculosis*. *Indian J. Exp. Biol.* **2009**, *47*, 393–400.

113. Gutierrez, M.; Saka, H.; Chinen, I.; Zoppino, F.; Yoshimori, T.; Bocco, J.; Colombo, M. Protective role of autophagy against *Vibrio cholerae* cytolysin, a pore-forming toxin from *V. cholerae*. *Proc. Natl. Acad. Sci. USA* **2007**, *104*, 1829–1834.

114. Thelestam, M.; Mollby, R. Survival of cultured cells after functional and structural disorganization of plasma membrane by bacterial haemolysins and phospholipases. *Toxicon* **1983**, *21*, 805–815.

115. Walev, I.; Palmer, M.; Martin, E.; Jonas, D.; Weller, U.; Hohn-Bentz, H.; Husmann, M.; Bhakdi, S. Recovery of human fibroblasts from attack by the pore-forming alpha-toxin of *Staphylococcus aureus*. *Microb Pathog.* **1994**, *17*, 187–201.

116. Dragneva, Y.; Anuradha, C.D.; Valeva, A.; Hoffmann, A.; Bhakdi, S.; Husmann, M. Subcytocidal attack by staphylococcal alpha-toxin activates NF-kappaB and induces interleukin-8 production. *Infec. Immun.* **2001**, *69*, 2630–2635.
117. Walev, I.; Hombach, M.; Bobkiewicz, W.; Fenske, D.; Bhakdi, S.; Husmann, M. Resealing of large transmembrane pores produced by streptolysin O in nucleated cells is accompanied by NF-kappaB activation and downstream events. *FASEB. J.* **2002**, *16*, 237–239.

118. Haugwitz, U.; Bobkiewicz, W.; Han, S.R.; Beckmann, E.; Veerachato, G.; Shaid, S.; Biehl, S.; Dersch, K.; Bhakdi, S.; Husmann, M. Pore-forming Staphylococcus aureus alpha-toxin triggers epidermal growth factor receptor-dependent proliferation. *Cell Microbiol.* **2006**, *8*, 1591–1600.

119. Kloft, N.; Neukirch, C.; Bobkiewicz, W.; Veerachato, G.; Busch, T.; von Hoven, G.; Boller, K.; Husmann, M. Pro-autophagic signal induction by bacterial pore-forming toxins. *Med. Microbiol. Immunol.* **2010**, *199*, 299–309.

120. Von Hoven, G.; Kloft, N.; Neukirch, C.; Ebinger, S.; Bobkiewicz, W.; Weis, S.; Boller, K.; Janda, K.; Husmann, M. Modulation of translation and induction of autophagy by bacterial exoproducts. *Med. Microbiol. Immunol.* **2012**, *201*, 409–418.

121. Nakagawa, I.; Amano, A.; Mizushima, N.; Yamamoto, A.; Yamaguchi, H.; Kamimoto, T.; Nara, A.; Funao, J.; Nakata, M.; Tsuda, K.; *et al*. Autophagy defends cells against invading group A Streptococcus. *Science* **2004**, *306*, 1037–1040.

122. von Muhlinen, N.; Thurston, T.; Ryzhakov, G.; Bloor, S.; Randow, F. NDP52, a novel autophagy receptor for ubiquitin-decorated cytosolic bacteria. *Autophagy* **2010**, *6*, 288–289.

123. Mestre, M.B.; Fader, C.M.; Sola, C.; Colombo, M.I. Alpha-hemolysin is required for the activation of the autophagic pathway in Staphylococcus aureus-infected cells. *Autophagy* **2010**, *6*, 110–125.

124. Mostowy, S.; Cossart, P. Bacterial autophagy: Restriction or promotion of bacterial replication? *Trends Cell Biol.* **2012**, *22*, 283–291.

125. Yoshikawa, Y.; Ogawa, M.; Hain, T.; Yoshida, M.; Fukumatsu, M.; Kim, M.; Mimuro, H.; Nakagawa, I.; Yanagawa, T.; Ishii, T.; *et al*. Listeria monocytogenes ActA-mediated escape from autophagic recognition. *Nat. Cell Biol.* **2009**, *11*, 1233–1240.

126. Tallozzy, Z.; Jiang, W.; Virgin, H.W., 4th; Leib, D.A.; Scheuner, D.; Kaufman, R.J.; Eskelinen, E.L.; Levine, B. Regulation of starvation- and virus-induced autophagy by the eIF2alpha kinase signaling pathway. *Proc. Natl. Acad. Sci. USA* **2002**, *99*, 190–195.

127. Powers, M.E.; Bubeck Wardenburg, J. Host autophagy combating S. aureus: Alpha-toxin will be tolerated. *Cell Host Microbe* **2015**, *17*, 419–420.

128. Inoshima, I.; Inoshima, N.; Wilke, G.A.; Powers, M.E.; Frank, K.M.; Wang, Y.; Bubeck Wardenburg, J. A Staphylococcus aureus pore-forming toxin subverts the activity of ADAM10 to cause lethal infection in mice. *Nat. Med.* **2011**, *17*, 1310–1314.

129. Powers, M.E.; Kim, H.K.; Wang, Y.; Bubeck Wardenburg, J. ADAM10 mediates vascular injury induced by Staphylococcus aureus alpha-hemolysin. *J. Infect. Dis.* **2012**, *206*, 352–356.

130. Maurer, K.; Torres, V.J.; Cadwell, K. Autophagy is a key tolerance mechanism during Staphylococcus aureus infection. *Autophagy* **2015**, *11*, 1184–1186.

131. Maurer, K.; Reyes-Robles, T.; Alonzo, F., 3rd; Durbin, J.; Torres, V.J.; Cadwell, K. Autophagy mediates tolerance to Staphylococcus aureus alpha-toxin. *Cell Host Microbe* **2015**, *17*, 429–440.

132. Genisset, C.; Puhar, A.; Calore, F.; de Bernard, M.; Dell’Antone, P.; Montecucco, C. The concerted action of the Helicobacter pylori cytotoxin VacA and of the v-ATPase proton pump induces swelling of isolated endosomes. *Cell Microbiol.* **2007**, *9*, 1481–1490.
133. Henry, R.; Shaughnessy, L.; Loessner, M.J.; Alberti-Segui, C.; Higgins, D.E.; Swanson, J.A. Cytolysin-dependent delay of vacuole maturation in macrophages infected with Listeria monocytogenes. *Cell Microbiol.* **2006**, *8*, 107–119.

134. Birmingham, C.L.; Canadien, V.; Kaniuk, N.A.; Steinberg, B.E.; Higgins, D.E.; Brumell, J.H. Listeriolysin O allows Listeria monocytogenes replication in macrophage vacuoles. *Nature* **2008**, *451*, 350–354.

135. Ligeon, L.; Moreau, K.; Barois, N.; Bongiovanni, A.; Lacorre, D.; Werkmeister, E.; Proux-Gillardeaux, V.; Galli, T.; Lafont, F. Role of VAMP3 and VAMP7 in the commitment of Yersinia pseudotuberculosis to LC3-associated pathways involving single- or double-membrane vacuoles. *Autophagy* **2014**, *10*, 1588–1602.

136. Gupta, M.; Shin, D.M.; Ramakrishna, L.; Goussetis, D.J.; Platanias, L.C.; Xiong, H.; Morse, H.C., 3rd; Ozato, K. IRF8 directs stress-induced autophagy in macrophages and promotes clearance of Listeria monocytogenes. *Nat. Commun.* **2015**, *6*, 6379.

137. Greenfield, L.K.; Jones, N.L. Modulation of autophagy by Helicobacter pylori and its role in gastric carcinogenesis. *Trends Microbiol.* **2013**, *21*, 602–612.

138. Terebiznik, M.; Raju, D.; Vazquez, C.; Torbricki, K.; Kulkarni, R.; Blanke, S.; Yoshimori, T.; Colombo, M.; Jones, N. Effect of Helicobacter pylori’s vacuolating cytotoxin on the autophagy pathway in gastric epithelial cells. *Autophagy* **2009**, *5*, 370–379.

139. Thammavongsa, V.; Kern, J.; Missiakas, D.; Schneewind, O. Staphylococcus aureus synthesizes adenosine to escape host immune responses. *J. Exp. Med.* **2009**, *206*, 2417–2427.

140. Tournier, J.; Quesnel-Hellmann, A.; Mathieu, J.; Montecucco, C.; Tang, W.; Mock, M.; Vidal, D.; Goossens, P. Anthrax edema toxin cooperates with lethal toxin to impair cytokine secretion during infection of dendritic cells. *J. Immunol.* **2005**, *174*, 4934–4941.

141. Shahnazari, S.; Namolovan, A.; Mogridge, J.; Kim, P.; Brumell, J. Bacterial toxins can inhibit host cell autophagy through cAMP generation. *Autophagy* **2011**, *7*, 957–965.

142. Tattoli, I.; Sorbara, M.; Vuckovic, D.; Ling, A.; Soares, F.; Carneiro, L.; Yang, C.; Emili, A.; Philpott, D.; Girardin, S. Amino acid starvation induced by invasive bacterial pathogens triggers an innate host defense program. *Cell Host Microbe* **2012**, *11*, 563–575.

143. Dong, N.; Zhu, Y.; Lu, Q.; Hu, L.; Zheng, Y.; Shao, F. Structurally distinct bacterial TBC-like GAPs link Arf GTPase to Rab1 inactivation to counteract host defenses. *Cell* **2012**, *150*, 1029–1041.

144. Ogawa, M.; Yoshimori, T.; Suzuki, T.; Sagara, H.; Mizushima, N.; Sasakawa, C. Escape of intracellular Shigella from autophagy. *Science* **2005**, *307*, 727–731.
149. Hamon, M.A.; Ribet, D.; Stavru, F.; Cossart, P. Listeriolysin O: The Swiss army knife of Listeria. *Trends Microbiol.* **2012**, **20**, 360–368.

150. Smith, G.A.; Marquis, H.; Jones, S.; Johnston, N.C.; Portnoy, D.A.; Goldfine, H. The two distinct phospholipases C of Listeria monocytogenes have overlapping roles in escape from a vacuole and cell-to-cell spread. *Infect. Immun.* **1995**, **63**, 4231–4237.

151. Picking, W.L.; Nishioka, H.; Hearn, P.D.; Baxter, M.A.; Harrington, A.T.; Blocker, A.; Picking, W.D. IpaD of Shigella flexneri is independently required for regulation of Ipa protein secretion and efficient insertion of IpaB and IpaC into host membranes. *Infect. Immun.* **2005**, **73**, 1432–1440.

152. D'Cruze, T.; Gong, L.; Treerat, P.; Ramm, G.; Boyce, J.; Prescott, M.; Adler, B.; Devenish, R. Role for the Burkholderia pseudomallei type three secretion system cluster 1 bpscN gene in virulence. *Infect. Immun.* **2011**, **79**, 3659–3664.

153. Chong, A.; Wehrly, T.; Child, R.; Hansen, B.; Hwang, S.; Virgin, H.; Celli, J. Cytosolic clearance of replication-deficient mutants reveals Francisella tularensis interactions with the autophagic pathway. *Autophagy* **2012**, **8**, 1342–1356.

154. Checroun, C.; Wehrly, T.; Fischer, E.; Hayes, S.; Celli, J. Autophagy-mediated reentry of Francisella tularensis into the endocytic compartment after cytoplasmic replication. *Proc. Natl. Acad. Sci. USA* **2006**, **103**, 14578–14583.

155. Huang, J.; Brumell, J. Bacteria-autophagy interplay: A battle for survival. *Nat. Rev. Microbiol.* **2014**, **12**, 101–114.

156. Asrat, S.; de Jesus, D.; Hempstead, A.; Ramabhadran, V.; Isberg, R. Bacterial pathogen manipulation of host membrane trafficking. *Annu. Rev. Cell Dev. Biol.* **2014**, **30**, 79–109.

157. Py, B.; Lipinski, M.; Yuan, J. Autophagy limits Listeria monocytogenes intracellular growth in the early phase of primary infection. *Autophagy* **2007**, **3**, 117–125.

158. Dortet, L.; Mostowy, S.; Cossart, P. Listeria and autophagy escape: Involvement of InlK, an internalin-like protein. *Autophagy* **2012**, **8**, 132–134.

159. Feoktistov, I.; Biaggioni, I. Adenosine A2B receptors. *Pharmacol. Rev.* **1997**, **49**, 381–402.

160. Budovsky, Y.; Stephan, J.; Deminoff, S.; Herman, P. An evolutionary proteomics approach identifies substrates of the cAMP-dependent protein kinase. *Proc. Natl. Acad. Sci. USA* **2005**, **102**, 13933–13938.

161. Stephan, J.; Yeh, Y.; Ramachandran, V.; Deminoff, S.; Herman, P. The Tor and PKA signaling pathways independently target the Atg1/Atg13 protein kinase complex to control autophagy. *Proc. Natl. Acad. Sci. USA* **2009**, **106**, 17049–17054.

162. Yorimitsu, T.; Zaman, S.; Broach, J.; Klionsky, D. Protein kinase A and Sch9 cooperatively regulate induction of autophagy in Saccharomyces cerevisiae. *Mol. Biol. Cell* **2007**, **18**, 4180–4189.

163. Dal Molin, F.; Zornetta, I.; Puhar, A.; Tonello, F.; Zaccolo, M.; Montecucco, C. cAMP imaging of cells treated with pertussis toxin, cholera toxin, and anthrax edema toxin. *Biochem. Biophys. Res. Commun.* **2008**, **376**, 429–433.

164. Alonso, S.; Pethe, K.; Russell, D.; Purdy, G. Lysosomal killing of Mycobacterium mediated by ubiquitin-derived peptides is enhanced by autophagy. *Proc. Natl. Acad. Sci. USA* **2007**, **104**, 6031–6036.
165. Ponpuak, M.; Davis, A.; Roberts, E.; Delgado, M.; Dinkins, C.; Zhao, Z.; Virgin, H.W.; Kyei, G.; Johansen, T.; Vergne, I.; et al. Delivery of cytosolic components by autophagic adaptor protein p62 endows autophagosomes with unique antimicrobial properties. *Immunity* 2010, 32, 329–341.

166. Butchar, J.; Cremer, T.; Clay, C.; Gavrilin, M.; Wewers, M.; Marsh, C.; Schlesinger, L.; Trindadapani, S. Microarray analysis of human monocytes infected with Francisella tularensis identifies new targets of host response subversion. *PLoS ONE* 2008, 3, e2924.

167. Zhao, Z.; Fux, B.; Goodwin, M.; Dunay, I.; Strong, D.; Miller, B.; Cadwell, K.; Delgado, M.; Ponpuak, M.; Green, K.; et al. Autophagosome-independent essential function for the autophagy protein Atg5 in cellular immunity to intracellular pathogens. *Cell Host Microbe* 2008, 4, 458–469.

168. Barnett, T.C.; Liebl, D.; Seymour, L.M.; Gillen, C.M.; Lim, J.Y.; Larock, C.N.; Davies, M.R.; Schulz, B.L.; Nizet, V.; Teasdale, R.D.; et al. The globally disseminated M1T1 clone of group A Streptococcus evades autophagy for intracellular replication. *Cell Host Microbe* 2013, 14, 675–682.

169. Grumati, P.; Coletto, L.; Schiavinato, A.; Castagnaro, S.; Bertaggia, E.; Sandri, M.; Bonaldo, P. Physical exercise stimulates autophagy in normal skeletal muscles but is detrimental for collagen VI-deficient muscles. *Autophagy* 2011, 7, 1415–1423.

170. Liu, X.; Niu, Y.; Yuan, H.; Huang, J.; Fu, L. AMPK binds to Sestrins and mediates the effect of exercise to increase insulin-sensitivity through autophagy. *Metabolism* 2015, 64, 658–665.

171. Thullier, P.; Avril, A.; Mathieu, J.; Behrens, C.; Pellequer, J.; Pelat, T. Mapping the epitopes of a neutralizing antibody fragment directed against the lethal factor of Bacillus anthracis and cross-reacting with the homologous edema factor. *PLoS ONE* 2013, 8, e65855.

172. Avril, A.; Froude, J.; Mathieu, J.; Pelat, T.; Thullier, P. Isolation of antibodies from non-human primates for clinical use. *Curr. Drug Discov. Technol.* 2014, 11, 20–27.

173. Tonello, F.; Seveso, M.; Marin, O.; Mock, M.; Montecucco, C. Screening inhibitors of anthrax lethal factor. *Nature* 2002, 418, 386.

174. Karanasios, E.; Ktistakis, N.T. Live-cell imaging for the assessment of the dynamics of autophagosome formation: Focus on early steps. *Methods* 2015, 75, 54–60.

175. Sarkar, S.; Perlstein, E.O.; Imarisio, S.; Pineau, S.; Cordenier, A.; Maglathlin, R.L.; Webster, J.A.; Lewis, T.A.; O’Kane, C.J.; Schreiber, S.L.; et al. Small molecules enhance autophagy and reduce toxicity in Huntington’s disease models. *Nat. Chem. Biol.* 2007, 3, 331–338.

176. Zhang, L.; Yu, J.; Pan, H.; Hu, P.; Hao, Y.; Cai, W.; Zhu, H.; Yu, A.D.; Xie, X.; Ma, D.; et al. Small molecule regulators of autophagy identified by an image-based high-throughput screen. *Proc. Natl. Acad. Sci. USA* 2007, 104, 19023–19028.

177. Hundeshagen, P.; Hamacher-Brady, A.; Eils, R.; Brady, N.R. Concurrent detection of autolysosome formation and lysosomal degradation by flow cytometry in a high-content screen for inducers of autophagy. *BMC Biol.* 2011, 9, 38.

178. Joachim, J.; Jiang, M.; McKnight, N.C.; Howell, M.; Tooze, S.A. High-throughput screening approaches to identify regulators of mammalian autophagy. *Methods* 2015, 75, 96–104.

179. Jiang, P.; Mizushima, N. LC3- and p62-based biochemical methods for the analysis of autophagy progression in mammalian cells. *Methods* 2015, 75, 13–18.
180. Rhee, H.W.; Zou, P.; Udeshi, N.D.; Martell, J.D.; Mootha, V.K.; Carr, S.A.; Ting, A.Y. Proteomic mapping of mitochondria in living cells via spatially restricted enzymatic tagging. *Science* **2013**, *339*, 1328–1331.

181. Levine, B.; Packer, M.; Codogno, P. Development of autophagy inducers in clinical medicine. *J. Clin. Invest.* **2015**, *125*, 14–24.

182. Wild, P.; Farhan, H.; McEwan, D.G.; Wagner, S.; Rogov, V.V.; Brady, N.R.; Richter, B.; Korac, J.; Waidmann, O.; Choudhary, C.; *et al.* Phosphorylation of the autophagy receptor optineurin restricts Salmonella growth. *Science* **2011**, *333*, 228–233.

183. Popov, S.; Popova, T.; Kashanchi, F.; Bailey, C. Targeting the inflammasome and adenosine type-3 receptors improves outcome of antibiotic therapy in murine anthrax. *World J. Biol. Chem.* **2011**, *2*, 98–104.

184. Nakahira, K.; Choi, A. Autophagy: A potential therapeutic target in lung diseases. *Am. J. Physiol. Lung Cell Mol. Physiol.* **2013**, *305*, L93–L107.

185. Vakifahmetoglu-Norberg, H.; Xia, H.G.; Yuan, J. Pharmacologic agents targeting autophagy. *J. Clin. Invest.* **2015**, *125*, 5–13.

186. Sarkar, S. Regulation of autophagy by mTOR-dependent and mTOR-independent pathways: Autophagy dysfunction in neurodegenerative diseases and therapeutic application of autophagy enhancers. *Biochem. Soc. Trans.* **2013**, *41*, 1103–1130.

187. Zhang, M.Z.; Wang, Y.; Paueksakon, P.; Harris, R.C. Epidermal growth factor receptor inhibition slows progression of diabetic nephropathy in association with a decrease in endoplasmic reticulum stress and an increase in autophagy. *Diabetes* **2014**, *63*, 2063–2072.

188. Sarkar, S. Chemical screening platforms for autophagy drug discovery to identify therapeutic candidates for Huntington’s disease and other neurodegenerative disorders. *Drug Discov. Today Technol.* **2013**, *10*, e137–e144.

189. Lonskaya, I.; Hebron, M.L.; Desforges, N.M.; Schachter, J.B.; Moussa, C.E. Nilotinib-induced autophagic changes increase endogenous parkin level and ubiquitination, leading to amyloid clearance. *J. Mol. Med. (Berl)* **2014**, *92*, 373–386.

190. Wang, L.; Chiang, H.C.; Wu, W.; Liang, B.; Xie, Z.; Yao, X.; Ma, W.; Du, S.; Zhong, Y. Epidermal growth factor receptor is a preferred target for treating amyloid-beta-induced memory loss. *Proc. Natl. Acad. Sci. USA* **2012**, *109*, 16743–16748.

191. Hidvegi, T.; Ewing, M.; Hale, P.; Dippold, C.; Beckett, C.; Kemp, C.; Maurice, N.; Mukherjee, A.; Goldbach, C.; Watkins, S.; *et al.* An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis. *Science* **2010**, *329*, 229–232.

192. Conway, K.L.; Kuballa, P.; Song, J.H.; Patel, K.K.; Castoreno, A.B.; Yilmaz, O.H.; Jijon, H.B.; Zhang, M.; Aldrich, L.N.; Villalba, E.J.; *et al.* Atg16l1 is required for autophagy in intestinal epithelial cells and protection of mice from Salmonella infection. *Gastroenterology* **2013**, *145*, 1347–1357.

193. Parihar, S.P.; Guler, R.; Khutlang, R.; Lang, D.M.; Hurdayal, R.; Mhlanga, M.M.; Suzuki, H.; Marais, A.D.; Brombacher, F. Statin therapy reduces the mycobacterium tuberculosis burden in human macrophages and in mice by enhancing autophagy and phagosome maturation. *J. Infect. Dis.* **2014**, *209*, 754–763.
194. Ravikumar, B.; Duden, R.; Rubinsztein, D.C. Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. *Hum. Mol. Genet.* 2002, 11, 1107–1117.
195. Ravikumar, B.; Vacher, C.; Berger, Z.; Davies, J.E.; Luo, S.; Oroz, L.G.; Scaravilli, F.; Easton, D.F.; Duden, R.; O’Kane, C.J.; *et al.* Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. *Nat. Genet.* 2004, 36, 585–595.
196. Williams, A.; Sarkar, S.; Cuddon, P.; Ttofi, E.K.; Saiki, S.; Siddiqi, F.H.; Jahreiss, L.; Fleming, A.; Pask, D.; Goldsmith, P.; *et al.* Novel targets for Huntington’s disease in an mTOR-independent autophagy pathway. *Nat. Chem. Biol.* 2008, 4, 295–305.
197. Meley, D.; Bauvy, C.; Houben-Weerts, J.H.; Dubbelhuis, P.F.; Helmond, M.T.; Codogno, P.; Meijer, A.J. AMP-activated protein kinase and the regulation of autophagic proteolysis. *J. Biol. Chem.* 2006, 281, 34870–34879.
198. Kim, J.; Kundu, M.; Viollet, B.; Guan, K.L. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. *Nat. Cell Biol.* 2011, 13, 132–141.
199. Kim, J.; Lee, H.; Shin, D.; Kim, W.; Yuk, J.; Jin, H.; Lee, S.; Cha, G.; Kim, J.; Lee, Z.; *et al.* Host cell autophagy activated by antibiotics is required for their effective antimycobacterial drug action. *Cell Host Microbe* 2012, 11, 457–468.
200. Yuk, J.; Shin, D.; Lee, H.; Yang, C.; Jin, H.; Kim, K.; Lee, Z.; Lee, S.; Kim, J.; Jo, E. Vitamin D3 induces autophagy in human monocytes/macrophages via cathelicidin. *Cell Host Microbe* 2009, 6, 231–243.
201. Fabri, M.; Modlin, R. A vitamin for autophagy. *Cell Host Microbe* 2009, 6, 201–203.
202. Mohammed, B.; Fisher, B.; Kraskauskas, D.; Farkas, D.; Brophy, D.; Fowler, A.A.; Natarajan, R. Vitamin C: A novel regulator of neutrophil extracellular trap formation. *Nutrients* 2013, 5, 3131–3151.
203. Wagner, J.; Birmingham, N.; Jackson-Humbles, D.; Jiang, Q.; Harkema, J.; Peden, D. Supplementation with gamma-tocopherol attenuates endotoxin-induced airway neutrophil and mucous cell responses in rats. *Free Radic Biol. Med.* 2014, 68, 101–109.
204. Sarkar, S.; Floto, R.A.; Berger, Z.; Imarisio, S.; Cordenier, A.; Pasco, M.; Cook, L.J.; Rubinsztein, D.C. Lithium induces autophagy by inhibiting inositol monophosphatase. *J. Cell Biol.* 2005, 170, 1101–1111.
205. Shaw, S.; Tran, K.; Castoreno, A.; Peloquin, J.; Lassen, K.; Khor, B.; Aldrich, L.; Tan, P.; Graham, D.; Kuballa, P.; *et al.* Selective modulation of autophagy, innate immunity, and adaptive immunity by small molecules. *ACS Chem. Biol.* 2013, 8, 2724–2733.
206. Parihar, S.; Guler, R.; Lang, D.; Suzuki, H.; Marais, A.; Brombacher, F. Simvastatin Enhances Protection against Listeria monocytogenes Infection in Mice by Counteracting Listeria-Induced Phagosomal Escape. *PLoS ONE* 2013, 8, e75490.
207. Uto, T.; Qin, G.W.; Morinaga, O.; Shoyama, Y. 17-Hydroxy-jolkinolide B, a diterpenoid from Euphorbia fischeriana, inhibits inflammatory mediators but activates heme oxygenase-1 expression in lipopolysaccharide-stimulated murine macrophages. *Int. Immunopharmacol.* 2012, 12, 101–109.
208. Sarkar, S.; Korolchuk, V.I.; Renna, M.; Imarisio, S.; Fleming, A.; Williams, A.; Garcia-Arencibia, M.; Rose, C.; Luo, S.; Underwood, B.R.; *et al.* Complex inhibitory effects of nitric oxide on autophagy. *Mol. Cell* 2011, 43, 19–32.
209. Opipari, A.W., Jr.; Tan, L.; Boitano, A.E.; Sorenson, D.R.; Aurora, A.; Liu, J.R. Resveratrol-induced autophagocytosis in ovarian cancer cells. *Cancer Res.* **2004**, *64*, 696–703.

210. Armour, S.M.; Baur, J.A.; Hsieh, S.N.; Land-Bracha, A.; Thomas, S.M.; Sinclair, D.A. Inhibition of mammalian S6 kinase by resveratrol suppresses autophagy. *Aging (Albany NY)* **2009**, *1*, 515–528.

211. Jeong, J.K.; Moon, M.H.; Bae, B.C.; Lee, Y.J.; Seol, J.W.; Kang, H.S.; Kim, J.S.; Kang, S.J.; Park, S.Y. Autophagy induced by resveratrol prevents human prion protein-mediated neurotoxicity. *Neurosci. Res.* **2012**, *73*, 99–105.

212. Li, W.; Zhu, S.; Li, J.; Assa, A.; Jundoria, A.; Xu, J.; Fan, S.; Eissa, N.T.; Tracey, K.J.; Sama, A.E.; *et al.* EGCG stimulates autophagy and reduces cytoplasmic HMGB1 levels in endotoxin-stimulated macrophages. *Biochem. Pharmacol.* **2011**, *81*, 1152–1163.

213. Kim, H.S.; Quon, M.J.; Kim, J.A. New insights into the mechanisms of polyphenols beyond antioxidant properties; lessons from the green tea polyphenol, epigallocatechin 3-gallate. *Redox Biol.* **2014**, *2*, 187–195.

214. Kandadi, M.; Yu, X.; Frankel, A.; Ren, J. Cardiac-specific catalase overexpression rescues anthrax lethal toxin-induced cardiac contractile dysfunction: Role of oxidative stress and autophagy. *BMC Med.* **2012**, *10*, 134.

215. Boya, P.; Gonzalez-Polo, R.A.; Casares, N.; Perfettini, J.L.; Dessen, P.; Larochette, N.; Metivier, D.; Meley, D.; Souquere, S.; Yoshimori, T.; *et al.* Inhibition of macroautophagy triggers apoptosis. *Mol. Cell Biol.* **2005**, *25*, 1025–1040.

216. Amaravadi, R.K.; Yu, D.; Lum, J.J.; Bui, T.; Christophorou, M.A.; Evan, G.I.; Thomas-Tikhonenko, A.; Thompson, C.B. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. *J. Clin. Invest.* **2007**, *117*, 326–336.

217. Punnonen, E.L.; Reunanen, H. Effects of vinblastine, leucine, and histidine, and 3-methyladenine on autophagy in Ehrlich ascites cells. *Exp. Mol. Pathol.* **1990**, *52*, 87–97.

218. Reunanen, H.; Marttinen, M.; Hirsimaki, P. Effects of griseofulvin and nocodazole on the accumulation of autophagic vacuoles in Ehrlich ascites tumor cells. *Exp. Mol. Pathol.* **1988**, *48*, 97–102.

219. Webb, J.L.; Ravikumar, B.; Rubinsztein, D.C. Microtubule disruption inhibits autophagosome-lysosome fusion: Implications for studying the roles of aggresomes in polyglutamine diseases. *Int. J. Biochem. Cell Biol.* **2004**, *36*, 2541–2550.

220. Blommaart, E.F.; Krause, U.; Schellens, J.P.; Vreeling-Sindelarova, H.; Meijer, A.J. The phosphatidylinositol 3-kinase inhibitors wortmannin and LY294002 inhibit autophagy in isolated rat hepatocytes. *Eur. J. Biochem.* **1997**, *243*, 240–246.

221. Roe, N.; Xu, X.; Kandadi, M.; Hu, N.; Pang, J.; Weiser-Evans, M.; Ren, J. Targeted deletion of PTEN in cardiomyocytes renders cardiac contractile dysfunction through interruption of Pink1-AMPK signaling and autophagy. *Biochim. Biophys. Acta* **2014**, *1852*, 290–298.

222. Mostowy, S.; Boucontelet, L.; Mazon Moya, M.; Sirianni, A.; Boudinot, P.; Hollinshead, M.; Cossart, P.; Herbonnel, P.; Levraud, J.; Colucci-Guyon, E. The zebrafish as a new model for the *in vivo* study of Shigella flexneri interaction with phagocytes and bacterial autophagy. *PLoS Pathog.* **2013**, *9*, e1003588.
223. Laplante, M.; Sabatini, D. mTOR signaling in growth control and disease. Cell 2012, 149, 274–293.
224. Mizumura, K.; Cloonan, S.; Haspel, J.; Choi, A. The emerging importance of autophagy in pulmonary diseases. Chest 2012, 142, 1289–1299.
225. Lam, K.; Zheng, X.; Forestieri, R.; Balgi, A.; Nodwell, M.; Vollett, S.; Anderson, H.; Andersen, R.; Av-Gay, Y.; Roberge, M. Nitazoxanide stimulates autophagy and inhibits mTORC1 signaling and intracellular proliferation of Mycobacterium tuberculosis. PLoS Pathog. 2012, 8, e1002691.
226. Junkins, R.; McCormick, C.; Lin, T. The emerging potential of autophagy-based therapies in the treatment of cystic fibrosis lung infections. Autophagy, 2014, 10, 538–547.
227. Aguirre, A.; Lopez-Alonso, I.; Gonzalez-Lopez, A.; Amado-Rodriguez, L.; Batalla-Solis, E.; Astudillo, A.; Blazquez-Prieto, J.; Fernandez, A.; Galvan, J.; Dos Santos, C.; et al. Defective autophagy impairs ATF3 activity and worsens lung injury during endotoxemia. J. Mol. Med. (Berl) 2014, 92, 665–676.
228. Tsuchiya, T.; Higami, Y.; Komatsu, T.; Tanaka, K.; Honda, S.; Yamaza, H.; Chiba, T.; Ayabe, H.; Shimokawa, I. Acute stress response in calorie-restricted rats to lipopolysaccharide-induced inflammation. Mech. Ageing Dev. 2005, 126, 568–579.
229. Carchman, E.; Rao, J.; Loughran, P.; Rosengart, M.; Zuckerbraun, B. Heme oxygenase-1-mediated autophagy protects against hepatocyte cell death and hepatic injury from infection/sepsis in mice. Hepatology 2011, 53, 2053–2062.
230. Ryter, S.W.; Choi, A.M. Autophagy: An Integral Component of the Mammalian Stress Response. J. Biochem. Pharmacol. Res. 2013, 1, 176–188.
231. Kandadi, M.; Frankel, A.; Ren, J. Toll-like receptor 4 knockout protects against anthrax lethal toxin-induced cardiac contractile dysfunction: Role of autophagy. Br. J. Pharmacol. 2012, 167, 612–626.
232. Kim, E.; Chang, H.; Choi, H.; Shin, J.; Park, S.; Jo, Y.; Choi, E.; Baek, S.; Kim, B.; Chang, J.; et al. Autophagy induced by resveratrol suppresses alpha-MSH-induced melanogenesis. Exp. Dermatol. 2014, 23, 204–206.
233. Flemmig, J.; Remmler, J.; Rohring, F.; Arnhold, J. (-)-Epicatechin regenerates the chlorinating activity of myeloperoxidase in vitro and in neutrophil granulocytes. J. Inorg. Biochem. 2014, 130, 84–91.
234. Schmid, D.; Munz, C. Innate and adaptive immunity through autophagy. Immunity 2007, 27, 11–21.
235. Kandadi, M.; Hua, Y.; Ma, H.; Li, Q.; Kuo, S.; Frankel, A.; Ren, J. Anthrax lethal toxin suppresses murine cardiomyocyte contractile function and intracellular Ca2+ handling via a NADPH oxidase-dependent mechanism. PLoS ONE 2010, 5, e13335.
236. Dell’Aica, I.; Dona, M.; Tonello, F.; Piris, A.; Mock, M.; Montecucco, C.; Garbisa, S. Potent inhibitors of anthrax lethal factor from green tea. EMBO Rep. 2004, 5, 418–422.
237. Steinmann, J.; Buer, J.; Pietschmann, T.; Steinmann, E. Anti-infective properties of epigallocatechin-3-gallate (EGCG), a component of green tea. Br. J. Pharmacol. 2013, 168, 1059–1073.
238. Hashimoto, K.; Sakagami, H. Induction of apoptosis by epigallocatechin gallate and autophagy inhibitors in a mouse macrophage-like cell line. Anticancer Res. 2008, 28, 1713–1718.
239. Kim, H.S.; Montana, V.; Jang, H.J.; Parpura, V.; Kim, J.A. Epigallocatechin gallate (EGCG) stimulates autophagy in vascular endothelial cells: A potential role for reducing lipid accumulation. *J. Biol. Chem.* 2013, 288, 22693–22705.

240. Choi, M.; Kim, Y.; Jung, J.; Yang, S.; Lee, T.; Shin, D. Resveratrol induces autophagy through death-associated protein kinase 1 (DAPK1) in human dermal fibroblasts under normal culture conditions. *Exp. Dermatol.* 2013, 22, 491–494.

241. Hao, E.; Lang, F.; Chen, Y.; Zhang, H.; Cong, X.; Shen, X.; Su, G. Resveratrol alleviates endotoxin-induced myocardial toxicity via the Nrf2 transcription factor. *PLoS ONE* 2013, 8, e69452.

242. Baur, J.A.; Pearson, K.J.; Price, N.L.; Jamieson, H.A.; Lerin, C.; Kalra, A.; Prabhu, V.V.; Allard, J.S.; Lopez-Lluch, G.; Lewis, K.; *et al.* Resveratrol improves health and survival of mice on a high-calorie diet. *Nature* 2006, 444, 337–342.

243. Lagouge, M.; Argmann, C.; Gerhart-Hines, Z.; Meziane, H.; Lerin, C.; Daussin, F.; Messadeq, N.; Milne, J.; Lambert, P.; Elliott, P.; *et al.* Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. *Cell* 2006, 127, 1109–1122.

244. Baur, J.A. Resveratrol, sirtuins, and the promise of a DR mimetic. *Mech. Ageing Dev.* 2010, 131, 261–269.

245. Morselli, E.; Marino, G.; Bennetzen, M.V.; Eisenberg, T.; Megalou, E.; Schroeder, S.; Cabrera, S.; Benit, P.; Rustin, P.; Criollo, A.; *et al.* Spermidine and resveratrol induce autophagy by distinct pathways converging on the acetylproteome. *J. Cell Biol.* 2011, 192, 615–629.

246. Pietrocola, F.; Marino, G.; Lissa, D.; Vacchelli, E.; Malik, S.A.; Niso-Santano, M.; Zamzami, N.; Galluzzi, L.; Maiuri, M.C.; Kroemer, G. Pro-autophagic polyphenols reduce the acetylation of cytoplasmic proteins. *Cell Cycle* 2012, 11, 3851–3860.

247. Galli, F.; Battistoni, A.; Gambari, R.; Pompei, A.; Bragonzi, A.; Pilolli, F.; Iuliano, L.; Pirollo, M.; Dechecchi, M.; Cabrini, G. Oxidative stress and antioxidant therapy in cystic fibrosis. *Biochim. Biophys. Acta* 2012, 1822, 690–713.

248. Fabri, M.; Realegeno, S.; Jo, E.; Modlin, R. Role of autophagy in the host response to microbial infection and potential for therapy. *Curr. Opin. Immunol.* 2011, 23, 65–70.

249. Inoue, H.; Hase, K.; Segawa, A.; Takita, T. H89 (N-[2-p-bromocinnamylamino-ethyl]-5-isoquinolinesulphonamide) induces autophagy independently of protein kinase A inhibition. *Eur. J. Pharmacol.* 2013, 714, 170–177.

250. Sasaki, T.; Kuniyasu, H. Significance of AKT in gastric cancer (Review). *Int. J. Oncol.* 2014, 45, 2187–2192.

251. Hasko, G.; Nemeth, Z.; Vizi, E.; Salzman, A.; Szabo, C. An agonist of adenosine A3 receptors decreases interleukin-12 and interferon-gamma production and prevents lethality in endotoxemic mice. *Eur. J. Pharmacol.* 1998, 358, 261–268.

252. Lee, H.; Kim, M.; Joo, J.; Gallos, G.; Chen, J.; Emala, C. A3 adenosine receptor activation decreases mortality and renal and hepatic injury in murine septic peritonitis. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 2006, 291, R959–R969.

253. Csoka, B.; Nemeth, Z.; Rosenberger, P.; Eltzschig, H.; Spolarics, Z.; Pacher, P.; Selmeczy, Z.; Koscs, B.; Himer, L.; Vizi, E.; *et al.* A2B adenosine receptors protect against sepsis-induced mortality by dampening excessive inflammation. *J. Immunol.* 2010, 185, 542–550.
254. Yitzhaki, S.; Huang, C.; Liu, W.; Lee, Y.; Gustafsson, A.; Mentzer, R.J.; Gottlieb, R. Autophagy is required for preconditioning by the adenosine A1 receptor-selective agonist CCPA. *Basic Res. Cardiol.* **2009**, *104*, 157–167.

255. Factor, P.; Mutlu, G.; Chen, L.; Mohameed, J.; Akhmedov, A.; Meng, F.; Jilling, T.; Lewis, E.; Johnson, M.; Xu, A.; *et al.* Adenosine regulation of alveolar fluid clearance. *Proc. Natl. Acad. Sci. USA* **2007**, *104*, 4083–4088.

256. Hasko, G.; Linden, J.; Cronstein, B.; Pacher, P. Adenosine receptors: Therapeutic aspects for inflammatory and immune diseases. *Nat. Rev. Drug Discov.* **2008**, *7*, 759–770.

257. Karapetyan, Y.; Sferrazza, G.; Zhou, M.; Ottenberg, G.; Spicer, T.; Chase, P.; Fallahi, M.; Hodder, P.; Weissmann, C.; Lasmezas, C. Unique drug screening approach for prion diseases identifies tacrolimus and astemizole as antiprion agents. *Proc. Natl. Acad. Sci. USA* **2013**, *110*, 7044–7049.

258. Vu, K.; Gelli, A. Astemizole and an analogue promote fungicidal activity of fluconazole against Cryptococcus neoformans var. grubii and Cryptococcus gattii. *Med. Mycol.* **2010**, *48*, 255–262.

259. Chong, C.; Chen, X.; Shi, L.; Liu, J.; Sullivan, D.J. A clinical drug library screen identifies astemizole as an antimalarial agent. *Nat. Chem. Biol.* **2006**, *2*, 415–416.

260. Lieberman, L.; Higgins, D. A small-molecule screen identifies the antipsychotic drug pimozide as an inhibitor of Listeria monocytogenes infection. *Antimicrob. Agents Chemother.* **2009**, *53*, 756–764.

261. Lieberman, L.; Higgins, D. Inhibition of Listeria monocytogenes infection by neurological drugs. *Int. J. Antimicrob. Agents* **2010**, *35*, 292–296.

262. Endo, A. The discovery and development of HMG-CoA reductase inhibitors. *J. Lipid Res.* **1992**, *33*, 1569–1582.

263. Kwak, B.; Mulhaupt, F.; Myit, S.; Mach, F. Statins as a newly recognized type of immunomodulator. *Nat. Med.* **2000**, *6*, 1399–1402.

264. Liao, J.; Laufs, U. Pleiotropic effects of statins. *Annu. Rev. Pharmacol. Toxicol.* **2005**, *45*, 89–118.

265. Tleyjeh, I.; Kashour, T.; Hakim, F.; Zimmerman, V.; Erwin, P.; Sutton, A.; Ibrahim, T. Statins for the prevention and treatment of infections: A systematic review and meta-analysis. *Arch. Intern. Med.* **2009**, *169*, 1658–1667.

266. Schmidt, H.; Hennen, R.; Keller, A.; Russ, M.; Muller-Werdan, U.; Werdan, K.; Buerke, M. Association of statin therapy and increased survival in patients with multiple organ dysfunction syndrome. *Intensive Care Med.* **2006**, *32*, 1248–1251.

267. Sourraud, J.B.; Briolant, S.; Dormoi, J.; Mosnier, J.; Savini, H.; Baret, E.; Amalvic, R.; Soulard, R.; Rogier, C.; Pradines, B. Atorvastatin treatment is effective when used in combination with mefloquine in an experimental cerebral malaria murine model. *Malar J.* **2012**, *11*, 13.

268. Reis, P.A.; Estato, V.; da Silva, T.I.; d’Avila, J.C.; Siqueira, L.D.; Assis, E.F.; Bozza, P.T.; Bozza, F.A.; Tibirica, E.V.; Zimmerman, G.A.; *et al.* Statins decrease neuroinflammation and prevent cognitive impairment after cerebral malaria. *PLoS Pathog.* **2012**, *8*, e1003099.

269. Hotze, E.; Tweten, R. Membrane assembly of the cholesterol-dependent cytolysin pore complex. *Biochim. Biophys. Acta* **2012**, *1818*, 1028–1038.

270. Gonzalez, M.R.; Bischofberger, M.; Freche, B.; Ho, S.; Parton, R.G.; van der Goot, F.G. Pore-forming toxins induce multiple cellular responses promoting survival. *Cell Microbiol.* **2011**, *13*, 1026–1043.
271. Sun, Y.; Li, C.; Shu, Y.; Ju, X.; Zou, Z.; Wang, H.; Rao, S.; Guo, F.; Liu, H.; Nan, W.; et al. Inhibition of autophagy ameliorates acute lung injury caused by avian influenza A H5N1 infection. *Sci. Signal* **2012**, *5*, ra16.

272. Lo, S.; Yuan, S.; Hsu, C.; Cheng, Y.; Chang, Y.; Hsueh, H.; Lee, P.; Hsieh, Y. Lc3 over-expression improves survival and attenuates lung injury through increasing autophagosomal clearance in septic mice. *Ann. Surg.* **2013**, *257*, 352–363.

273. Schein, C.; Chen, D.; Ma, L.; Kanalas, J.; Gao, J.; Jimenez, M.; Sower, L.; Walter, M.; Gilbertson, S.; Peterson, J. Pharmacophore selection and redesign of non-nucleotide inhibitors of anthrax edema factor. *Toxins (Basel)* **2012**, *4*, 1288–1300.

274. Park, H.; Shin, J.; Kim, H.; Oh, S.; Lee, P. Neuroprotective effects of mesenchymal stem cells through autophagy modulation in a parkinsonian model. *Neurobiol. Aging* **2014**, *35*, 1920–1928.

275. Brandau, S.; Jakob, M.; Bruderek, K.; Bootz, F.; Giebel, B.; Radtke, S.; Mauel, K.; Jager, M.; Flohe, S.; Lang, S. Mesenchymal stem cells augment the anti-bacterial activity of neutrophil granulocytes. *PLoS ONE* **2014**, *9*, e106903.

© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).